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CORAL Cardiovascular Outcomes in Renal
Atherosclerotic Lesions
CPG Committee for Practice Guidelines
CPB Cardiopulmonary bypass
CREST Carotid Revascularization Endarterectomy versus
Stenting Trial
CTA Computed tomography angiography
CV Cardiovascular
DAPT Dual antiplatelet therapy
DES Drug eluting stent
DSA Digital subtraction angiography
DUS Duplex ultrasound
ECG Electrocardiogram
ECST European Carotid Surgery Trial
EPD Embolus protection device
ESC European Society of Cardiology
ESO European Stroke Organisation;
ESVS European Society of Vascular Surgery
EUCLID Effects of Ticagrelor and Clopidogrel in Patients
with Peripheral Artery Disease
EVA-3S Endarterectomy vs Stenting in Patients with
Symptomatic Severe Carotid Stenosis
EVT Endovascular therapy
ExT Exercise therapy
FMD Fibromuscular dysplasia
GSV Great saphenous vein
HDL-C High-density lipoprotein cholesterol
HF-ACTION Heart Failure: A Controlled Trial Investigating
Outcomes of Exercise Training
HITS High-intensity transient signal
HOPE Heart Outcomes Prevention Trial
HR Hazard ratio
IC Intermittent claudication
ICA Internal carotid artery
ICD Implantable cardioverter defibrillator
ICSS International Carotid Stenting Study
INR International normalized ratio
INVEST INternational VErapamil-SR/Trandolapril Study
LDL-C Low-density lipoprotein cholesterol
LEAD Lower extremity artery disease
LV Left ventricular
MACE Major adverse cardiovascular event
MI Myocardial infarction
MRA Magnetic resonance angiography
MR CLEAN MultiCenter Randomized Clinical Trial of Ischemic
Stroke in the Netherlands
MRI Magnetic resonance imaging
MSAD Multisite artery disease
MWD Maximal walking distance
NASCET North American Symptomatic Carotid
Endarterectomy Trial
NNH Number needed to harm
NNT Number needed to treat
NOAC Non-vitamin K oral anticoagulant
OAC Oral anticoagulation
ONTARGET Ongoing Telmisartan Alone and in Combination
With Ramipril Global Endpoint Trial
OR Odds ratio
PADs Peripheral arterial diseases
PCI Percutaneous coronary intervention
PEGASUS-
TIMI 54
Prevention of Cardiovascular Events in
Patients with Prior Heart Attack Using
Ticagrelor Compared to Placebo on a
Background of Aspirin–Thrombolysis in
Myocardial Infarction 54
PRODIGY PROlonging Dual antiplatelet treatment after
Grading stent-induced intimal hYperplasia study
PTA Percutaneous transluminal angioplasty
QOL Quality of life
RAAS Renin–angiotensin–aldosterone system
RAD Renal artery disease
RAS Renal artery stenosis
RCT Randomized clinical trial
REACH Reduction of Atherothrombosis for Continued
Health
ROCKET-AF Rivaroxaban Once Daily Oral Direct Factor Xa
Inhibition Compared with Vitamin K Antagonism
for Prevention of Stroke and Embolism Trial in
Atrial Fibrillation
RR Relative risk
RRI Renal resistive index
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SAPPHIRE Stenting and Angioplasty with Protection in
Patients at High Risk for Endarterectomy
SAPT Single antiplatelet therapy
SBP Systolic blood pressure
SFA Superficial femoral artery
SPACE Stent Protected Angioplasty versus Carotid
Endarterectomy
STAR Stent Placement in Patients With Atherosclerotic
Renal Artery Stenosis and Impaired Renal Function
TAMARIS Efficacy and Safety of XRP0038/NV1FGF in Critical
Limb Ischaemia Patients With Skin Lesions
TAVI Transcatheter aortic valve implantation
TBI Toe-brachial index
TcPO2 Transcutaneous oxygen pressure
TIA Transient ischaemic attack
TTE Transthoracic echocardiography
UEAD Upper extremity artery disease
VA Vertebral artery
VAST Vertebral Artery Stenting Trial
VHD Valvular heart disease
VKA Vitamin K antagonist
WD Walking distance
WIfI Wound, ischaemia and foot infection
1. Preamble
Guidelines summarize and evaluate available evidence with the aim of
assisting health professionals in selecting the best management strategies
for an individual patient with a given condition. Guidelines and their rec-
ommendations should facilitate decision making of health professionals
in their daily practice. However, the final decisions concerning an indi-
vidual patient must be made by the responsible health professional(s) in
consultation with the patient and caregiver as appropriate.
A great number of guidelines have been issued in recent years by
the European Society of Cardiology (ESC), by the European Society of
Vascular Surgery (ESVS) and by the European Stroke Organization
(ESO), as well as by other societies and organisations. Because of the
impact on clinical practice, quality criteria for the development of
guidelines have been established in order to make all decisions trans-
parent to the user. The recommendations for formulating and issuing
ESC Guidelines can be found on the ESC Website (https://www.escar
dio.org/Guidelines/Clinical-Practice-Guidelines/Guidelines-develop
ment/Writing-ESC-Guidelines). ESC Guidelines represent the official
position of the ESC on a given topic and are regularly updated.
Members of this Task Force were selected by the ESC, including
representation from the ESVS and ESO to represent professionals
involved with the medical care of patients with this pathology.
Selected experts in the field undertook a comprehensive review of
the published evidence for management of a given condition according
to ESC Committee for Practice Guidelines (CPG) policy and
approved by the ESVS and ESO. A critical evaluation of diagnostic and
therapeutic procedures was performed, including assessment of the
risk–benefit ratio. The level of evidence and the strength of the rec-
ommendation of particular management options were weighed and
graded according to predefined scales, as outlined in Tables 1 and 2.
The experts of the writing and reviewing panels provided declara-
tion of interest forms for all relationships that might be perceived as
real or potential sources of conflicts of interest. These forms were
compiled into one file and can be found on the ESC Website (http://
www.escardio.org/guidelines). Any changes in declarations of interest
that arise during the writing period were notified to the ESC and
updated. The Task Force received its entire financial support from the
ESC and ESVS without any involvement from the healthcare industry.
The ESC CPG supervises and coordinates the preparation of new
Guidelines. The Committee is also responsible for the endorsement
process of these Guidelines. The ESC Guidelines undergo extensive
review by the CPG and external experts, and in this case by ESVS- and
ESO-appointed experts. After appropriate revisions the Guidelines are
approved by all the experts involved in the Task Force. The finalized
document is approved by the CPG and ESVS for publication in the
European Heart Journal and in the European Journal of Vascular and
Table 1 Classes of recommendations
ESC Guidelines 767
D
ow
nloaded from
 https://academ
ic.oup.com
/eurheartj/article-abstract/39/9/763/4095038 by Theology Library, U
niversity of H
elsinki user on 10 M
ay 2019
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
Endovascular Surgery. The Guidelines were developed after careful
consideration of the scientific and medical knowledge and the evidence
available at the time of their dating.
The task of developing ESC Guidelines in collaboration with ESVS
also includes the creation of educational tools and implementation pro-
grammes for the recommendations including condensed pocket guide-
line versions, summary slides, booklets with essential messages,
summary cards for non-specialists and an electronic version for digital
applications (smartphones, etc.). These versions are abridged and thus, if
needed, one should always refer to the full text version, which is freely
available via the ESC Website and hosted on the EHJ Website. The
National Societies of the ESC are encouraged to endorse, translate and
implement all ESC Guidelines. Implementation programmes are needed
because it has been shown that the outcome of disease may be favour-
ably influenced by the thorough application of clinical recommendations.
Surveys and registries are needed to verify that real-life daily prac-
tice is in keeping with what is recommended in the guidelines, thus
completing the loop between clinical research, writing of guidelines,
disseminating them and implementing them into clinical practice.
Health professionals are encouraged to take the ESC Guidelines
developed in collaboration with ESVS fully into account when exer-
cising their clinical judgment, as well as in the determination and the
implementation of preventive, diagnostic or therapeutic medical
strategies. However, the ESC Guidelines do not override in any way
whatsoever the individual responsibility of health professionals to
make appropriate and accurate decisions in consideration of each
patient’s health condition and in consultation with that patient or the
patient’s caregiver where appropriate and/or necessary. It is also the
health professional’s responsibility to verify the rules and regulations
applicable to drugs and devices at the time of prescription.
2. Introduction
In 2011, the ESC published its first Guidelines on the Diagnosis and
Management of Peripheral Arterial Diseases.1 This publication filled an
important gap within the ESC Guidelines documents compendium.
Meanwhile, the ESVS released on a regular basis several guidelines docu-
ments on the management of specific localizations of arterial diseases.
Both societies emphasized the need for multidisciplinary management
of these patients. When the decision was made to update these guide-
lines, it appeared obvious that a combination of efforts from both soci-
eties would provide the most comprehensive single document,
providing updated guidelines on peripheral arterial diseases (PADs) for
clinicians.
It is of the outmost importance that every cardiologist should
be sensitive in regard to the diagnosis and management of patients with
PADs, as many of them are seen and managed for concomitant cardiac
conditions. In the ESC 2011 Guidelines, a specific chapter was dedi-
cated to patients with combined coronary and peripheral artery dis-
eases, as they mostly share the same aetiology and risk factors. In these
guidelines, the Task Force made a step forward and proposed a new
chapter on other cardiac conditions frequently encountered among
patients with PADs. Also, as the options for the use and combination
of antithrombotic drugs have increased, a specific chapter has been
dedicated to their use in the management of PADs. The current back-
ground information and detailed discussion of the data for the following
section of these Guidelines can be found in ESC CardioMed.
In this document, the term ‘peripheral arterial diseases’ encompasses
all arterial diseases other than coronary arteries and the aorta. This
should be clearly distinguished from the term ‘peripheral artery dis-
ease’, which is often used for lower extremity artery disease (LEAD).
Indeed, other peripheral localizations, including the carotid and verte-
bral, upper extremities, mesenteric and renal arteries, are also fre-
quently affected, mainly by atherosclerosis, and complete the family of
PADs. Regarding the carotid and vertebral arteries, this document cov-
ers only their extracranial segments, as specialists other than cardiolo-
gists and vascular surgeons often manage intracranial arterial diseases.
The Task Force has decided to address only PADs secondary to
atherosclerosis, with a few exceptions in specific areas where non-
atherosclerotic diseases are a frequent differential diagnosis (e.g.
fibromuscular dysplasia in renal arteries). For other cases, readers
should always bear in mind the possibility for non-atherosclerotic
conditions and refer to specific documents. Readers are also invited
to refer to the Web addenda for further information.
The ESC and ESVS also join their efforts to provide increased med-
ical and public awareness about PADs. Indeed, while stroke is
acknowledged as a serious condition with significant burden through-
out Europe, other PADs can be as lethal and disabling. Major efforts
are still necessary to sensitize healthcare providers, decision makers
and the general population about the need for earlier and more effi-
cient prevention and management strategies for the 40 million indi-
viduals of our continent affected by PADs.1,2
Table 2 Levels of evidence
General recommendations on the management of
patients with peripheral arterial diseases
Recommendations Classa Levelb
In healthcare centres, it is recommended to
set up a multidisciplinary Vascular Team to
make decisions for the management of
patients with PADs.
I C
It is recommended to implement and sup-
port initiatives to improve medical and pub-
lic awareness of PADs, especially
cerebrovascular and lower extremity artery
diseases.
I C
PADs = peripheral arterial diseases.
aClass of recommendation.
bLevel of evidence.
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3. Epidemiology and risk factors
Key messages
• Overall, the risk of different localizations of PADs increases
sharply with age and with exposure to major cardiovascular (CV)
risk factors, including smoking, hypertension, dyslipidaemia and
diabetes. Other risk factors are still under investigation.
• The strength of association between each risk factor and each
vascular territory is variable, but all the major risk factors should
be screened and considered.
• When a vascular territory is affected by atherosclerosis, not only
is the corresponding organ endangered [e.g. the brain for carotid
artery disease (CAD)], but also the total risk of any CV event is
increased (e.g. coronary events). Each vascular territory affected
by atherosclerosis can be considered as marker of CV risk.
3.1 Epidemiology
The epidemiology of different patterns of PADs is presented in the
Web addenda 3.1. The current background information and detailed
discussion of the data for the following section of these Guidelines
can be found in ESC CardioMed.
3.2 Risk factors
Although different localizations of PADs share common major risk
factors for atherosclerosis, the impact of those and/or available evi-
dence differ per arterial site. See Web addenda 3.2.
3.3 Prognosis
Atherosclerosis is often generalized. Patients affected at one site are
overall at risk for fatal and non-fatal CV events.
Beyond the risk of cerebrovascular events, patients with CAD are
also at risk for myocardial infarction (MI) and cardiac death.3 In a sys-
tematic review of 17 studies including 11 391 patients with >50%
asymptomatic carotid stenosis, 63% of late deaths were related to car-
diac events, with a mean cardiac-related mortality rate of 2.9%/year.4
Many studies have shown an increased risk of mortality, CV mor-
tality and morbidity (MI, stroke) in patients with symptomatic or
asymptomatic LEAD, even after adjustment for conventional risk fac-
tors.5 An ankle-brachial index (ABI) <_0.90 is associated with more
than doubling of the 10-year rates of coronary events, CV mortality
and total mortality.6 After 5 years, 20% of patients with intermittent
claudication (IC) present an MI or stroke and mortality is 10–15%.7
All these data emphasize the importance of general CV prevention
beyond the management of the disease related to a specific site of
atherosclerosis.
4. General aspects
Key messages
• Thorough clinical history and physical examination are key steps
in PADs management.
• Beyond the diagnosis of LEAD, ABI is also a strong marker for
CV events.
• The management of PADs includes all interventions to address
specific arterial symptoms as well as general CV risk prevention.
• Best medical therapy includes CV risk factor management, including
optimal pharmacological therapy as well as non-pharmacological
measures such as smoking cessation, healthy diet, weight loss and
regular physical exercise.
4.1 Diagnostic approach
4.1.1 Clinical history
Personal and family clinical history should always be assessed. Family
history includes CAD, cerebrovascular disease, aortic aneurysm as
well as LEAD.8–10 Clinical history includes the evaluation of CV risk
factors and comorbidities as well as a review of the symptoms related
to different vascular territories (see Web Table 1). Lifestyle habits,
dietary patterns, walking performances and physical activity need to
be systematically interrogated. Physical activity should be assessed.11
Questionnaires and functional status provide reasonably accurate out-
come measures. They may be useful for determining the impairment
level and selection of appropriate care.12,13 The current background
information and detailed discussion of the data for the following sec-
tion of these Guidelines can be found in ESC CardioMed.
4.1.2 Clinical examination
Although physical examination alone is of relatively poor sensitivity and
reproducibility, a systematic approach is mandatory (see Web Table 2).
Beyond their diagnostic importance, clinical signs have a prognostic
value. Individuals with carotid bruits have twice the risk of MI and CV
death as compared with those without.14 Interarm blood pressure (BP)
asymmetry (>_15 mmHg) is a marker of vascular disease risk and death.15
A femoral bruit is an independent marker for ischaemic cardiac events.16
4.1.3 Laboratory testing
Investigations should progress from the ‘minimal’ biological assess-
ment17 to complementary laboratory tests if necessary (outlined in
Web Table 3).
4.1.4 Diagnostic methods for PADs
4.1.4.1 Ankle-brachial index
The ABI is a non-invasive tool useful for the diagnosis and surveillance
of LEAD. It is also a strong marker of generalized atherosclerosis and
CV risk (see Table 3). An ABI <_0.90 is associated on average with a 2-
to 3-fold increased risk of total and CV death. An ABI >1.40 represents
arterial stiffening (medial arterial calcification) and is also associated
with a higher risk of CV events and mortality.6,18 It is more prevalent in
elderly patients, mostly in those with diabetes or chronic kidney dis-
ease (CKD). When added to a risk score, ABI enables the risk estima-
tion to be upgraded in one-third and one-fifth of ‘low-risk’ women and
men, respectively.6 It is a valid method of CV risk assessment in diverse
ethnic groups, independent of risk factors.18 In contrast to coronary
calcium score and carotid intima-media thickness, ABI is inexpensive
and minimally time consuming. Good training is mandatory.
In addition to the general CV risk, ABI measurement can identify a
patient’s risk for lower-extremities events, requiring close attention
and education for foot wound prevention.
4.1.4.2 Duplex ultrasound
Duplex ultrasound (DUS) is often a first step in the vascular workup
both for screening and diagnosis. DUS includes B-mode echography,
pulsed-wave, continuous, colour and power Doppler modalities to
detect and localize vascular lesions and quantify their extent and
severity through velocity criteria. More recent techniques, such as flow
imaging or live three-dimensional (3D) echography, as well as the use
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of ultrasound contrast agents, further improve DUS performances,
although their use is still limited. DUS can detect subclinical artery dis-
ease (e.g. carotid plaque), which is important for CV risk assessment.17
4.1.4.3 Digital subtraction angiography
Digital subtraction angiography (DSA) was considered the standard
reference in vascular imaging. Given its invasive character and risk of
complications, it has been mostly replaced by other less invasive
methods except for below-the-knee arterial disease. It may be used
in the case of discrepancy between non-invasive imaging tools.
4.1.4.4 Computed tomography angiography
Multidetector computed tomography angiography (CTA) has a short
examination time with reduced motion and respiration artefacts
while imaging vessels and organs. Advantages of CTA include rapid
non-invasive acquisition, wide availability, high resolution and 3D
reformatting. Similar to DSA and magnetic resonance angiography
(MRA), CTA displays a ‘roadmap’ of the vascularization, essential for
determining interventional strategies (lesion localization and severity,
upstream/downstream status). The drawbacks of CTA include the
lack of functional and haemodynamic data, exposure to radiation and
the use of iodinated contrast agents, which should be limited in the
case of CKD, with precautions in case of allergies. Nephrotoxicity
can be limited by minimizing contrast agent volume and ensuring
adequate hydration before and after imaging. The benefit of acetyl-
cysteine to limit nephrotoxicity is uncertain.19,20 Recent studies have
suggested that statins or sodium bicarbonate could prevent contrast
agent nephrotoxicity.21,22 Further research is required.
4.1.4.5 Magnetic resonance angiography
MRA is used for peripheral artery imaging using contrast (i.e. gadoli-
nium) and non-contrast techniques (i.e. phase contrast and time-of-
flight sequences). These latter techniques have inferior resolution
and are susceptible to artefacts, limiting their interpretation. They are
a valuable alternative for use in patients with mild to moderate CKD.
Compared with CTA, MRA does not need iodine contrast and has
higher soft tissue resolution; however, motion artefacts are more fre-
quent and contraindications include pacemakers and implantable car-
dioverter defibrillators (ICDs) [except magnetic resonance imaging
(MRI)-conditional and compatible pacemakers, ICDs and leads],
claustrophobia and severe CKD. In the latter case, the risk of nephro-
genic systemic fibrosis following gadolinium administration should
not be underestimated.23 Vascular calcifications, potentially affecting
revascularization procedures, can be underestimated. Endovascular
stents are not evaluable by MRI.
4.2 Treatment approach
The therapeutic approach to patients with PADs includes two aspects.
The first is to address specific symptoms of any localization and the
risk related to a specific lesion. This is addressed in the next sections.
The second aspect of management in these patients is related to
their increased risk of any CV event (see section 3.2). General CV
prevention is of the utmost importance and management should be
multidisciplinary. Best medical therapy (BMT) includes CV risk factor
management, including best pharmacological therapy, as well as non-
pharmacological measures such as smoking cessation, healthy diet,
weight loss and regular physical exercise.24,25 The pharmacological
Table 3 The Ankle-Brachial Index
AAA = abdominal aorta aneurysm; ABI = ankle-brachial index; BP = blood pressure;
CAD = coronary artery disease; CKD = chronic kidney disease; CV = cardiovascular;
ESC = European Society of Cardiology; LEAD = lower extremity artery disease; PADs
= peripheral arterial diseases; SBP = systolic blood pressure. aSubjects with: markedly
elevated single risk factors; diabetes mellitus (except for young people with type 1 dia-
betes without other major risk factors); a calculated SCORE >_5% and <10%.
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..component of BMT includes antihypertensive, lipid-lowering and
antithrombotic drugs. In diabetic patients, optimal glucose level con-
trol should be obtained as recommended.26
4.2.1 Smoking cessation
A body of evidence supports the benefits of smoking cessation in
reducing CV events and mortality, especially in patients with cerebro-
vascular disease and LEAD.27,28 Management and support for smok-
ing cessation was extensively addressed in the 2016 ESC guidelines
on CV disease prevention.25 Passive smoking should be assessed and
prevented.29
4.2.2 Lipid-lowering drugs
All patients with PADs should have their serum low-density lipopro-
tein cholesterol (LDL-C) reduced to < 1.8 mmol/L (<70 mg/dL) or
decreased by >_ 50% if the initial LDL-C level is between 1.8 and
3.5 mmol/L (70 and 135 mg/dL).25 In observational studies and limited
randomized clinical trials (RCTs) in patients with LEAD (from asymp-
tomatic to severe cases), statin therapy has been shown to cause
reductions in all-cause mortality and CV events.30–32 In the Reduction
of Atherothrombosis for Continued Health (REACH) registry, among
patients with LEAD, statin use was associated with a 17% decrease in
adverse CV events rates.33 Even in the most advanced stages of dis-
ease, statin therapy is associated with lower 1-year rates of mortality
and major CV adverse events.34 Combination treatment with ezeti-
mibe in selected patients is also beneficial.35 In a randomized trial,
bezafibrate showed no benefit over placebo to reduce coronary and
cerebrovascular events in patients with LEAD.36 In those with CAD,
statins reduce the stroke risk.37,38 Recently the Fourier trial demon-
strated the additional benefits of evolocumab, a monoclonal antibody
inhibiting the proprotein convertase subtilisin/kexin type 9 to reduce
CV events in patients with atherosclerotic disease over statins alone.39
The results were consistent in the subgroup of 1505 patients with
LEAD alone. Further results are awaited.
4.2.3 Antithrombotic drugs
Antiplatelet agents are used for secondary prevention of CV events
in patients with symptomatic PADs. The evidence is mostly available
in patients with LEAD and cerebrovascular disease (see chapter 5).
4.2.4 Antihypertensive drugs
Lowering systolic blood pressure (SBP) reduces CV events.40
According to the current ESC/European Society of Hypertension
guidelines,41 a target BP < 140/90 mmHg is recommended except in
patients with diabetes, for whom a diastolic blood pressure
<_85 mmHg is considered safe. In patients with LEAD, this is mainly
based on data from the INternational VErapamil-SR/Trandolapril
(INVEST) study.42 Caution should be exercised to avoid an SBP
decrease below 110–120 mmHg, since a J-shape relationship
between SBP and CV events has been reported in that trial in LEAD
patients.42 In old and frail patients, these levels should be achieved
only if well tolerated, without orthostatic hypotension.43,44 In
patients with PADs, an appropriate lifestyle and salt intake (<5–6 g/
day) are recommended.45 Diuretics, beta-blockers, calcium antago-
nists, angiotensin-converting enzyme inhibitors (ACEIs) and angioten-
sin receptor blockers (ARBs) are all suitable for antihypertensive
treatment, as monotherapy or in different combinations. In the
INVEST study, no difference in CV outcomes was found between the
verapamil plus trandolapril strategy vs. the atenolol plus hydrochloro-
thiazide strategy.42 Some classes may be preferred according to
comorbidities.41
The Heart Outcomes Prevention Trial (HOPE) and the Ongoing
Telmisartan Alone and in Combination With Ramipril Global
Endpoint Trial (ONTARGET) have shown that ACEIs and ARBs sig-
nificantly reduce CV events in patients with PADs.46,47 According to
these trials, ACEIs or ARBs are recommended for secondary preven-
tion, even in patients with chronic limb-threatening ischaemia (CLTI).
In this subgroup of patients, the use of ACEIs or ARBs is associated
with decreased major adverse cardiovascular events (MACEs) and
mortality without any effect on limb outcomes.48
Importantly, beta-blockers are not contraindicated in patients with
LEAD, as they do not alter walking capacity in patients with mild to
moderate LEAD.49 In an observational study, patients with LEAD and
prior MI and taking beta-blockers had a significant 53% coronary
events risk decrease at 32 months.50 Nevertheless, they should be
carefully prescribed to patients with CLTI.
Recommendations in patients with peripheral arterial
diseases: best medical therapy
Recommendations Classa Levelb
Smoking cessation is recommended in all
patients with PADs.27,28
I B
Healthy diet and physical activity are recom-
mended for all patients with PADs.
I C
Statins are recommended in all patients
with PADs.31,32
I A
In patients with PADs, it is recommended to
reduce LDL-C to < 1.8 mmol/L (70 mg/dL)
or decrease it by >_ 50% if baseline values
are 1.8–3.5 mmol/L (70–135 mg/dL).25
I C
In diabetic patients with PADs, strict glycae-
mic control is recommended.
I C
Antiplatelet therapy is recommended in
patients with symptomatic PADs.51
I C
d
In patients with PADs and hypertension, it is
recommended to control blood pressure
at < 140/90 mmHg.41,42,52
I A
ACEIs or ARBs should be considered as
first-line therapyc in patients with PADs and
hypertension.47,53
IIa B
ACEIs = angiotensin-converting enzyme inhibitors; ARBs = angiotensin-receptor
blockers; LDL-C = low-density lipoprotein cholesterol; PADs = peripheral arte-
rial diseases.
aClass of recommendation.
bLevel of evidence.
cCalcium channel blockers should be proposed in black individuals.
dEvidence is not available for all sites. When evidence is available, recommenda-
tions specific for the vascular site are presented in corresponding sections.
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..5. Antithrombotic drugs in
peripheral arterial diseases
Key messages
• Antiplatelet therapy is indicated in all patients with carotid artery
stenosis irrespective of clinical symptoms and revascularization.
Dual antiplatelet therapy (DAPT) should be given for at least
1 month after CAS.
• Single antiplatelet therapy (SAPT) is indicated only if LEAD
patients are symptomatic or have undergone revascularization.
Clopidogrel is the preferred antiplatelet drug in LEAD patients.
• Chronic anticoagulation therapy is given only if there is a con-
comitant indication and may be combined with SAPT when there
is a recent revascularization procedure.
Antiplatelet therapy is part of BMT for symptomatic PADs (see
chapter 4). The specific issues about CAD and LEAD are addressed
here. The question of DAPT after endovascular therapy in other
territories as well as the sensitive issue of PADs patients requiring
anticoagulation [e.g. with concomitant atrial fibrillation (AF)] are also
addressed. The current background information and detailed discus-
sion of the data for the following section of these Guidelines can be
found in ESC CardioMed.
5.1 Antithrombotic treatment in carotid
artery disease
5.1.1 Single antiplatelet therapy
While the benefit of SAPT for preventing stroke in asymptomatic
patients with carotid artery stenosis >50% is not evidenced
through an RCT, lifelong low-dose aspirin should be part of BMT
to reduce the risk of stroke and other CV events,54 as these
patients are also at twice the risk of MI.14 In symptomatic extracra-
nial carotid stenosis, antiplatelet monotherapy is recom-
mended.54,55 Clopidogrel (75 mg/day) is an alternative in patients
with aspirin intolerance.51
5.1.2 Dual antiplatelet therapy
In the randomized Clopidogrel for High Atherothrombotic Risk and
Ischemic Stabilization, Management and Avoidance (CHARISMA)
trial, asymptomatic CAD was an inclusion criteria in 7% of patients
enrolled. No benefit was observed between DAPT vs. SAPT.56 The
Clopidogrel and Aspirin for the Reduction of Emboli in Symptomatic
carotid Stenosis (CARESS) study, conducted in 108 patients, demon-
strated that DAPT vs. aspirin reduced silent cerebral micro-emboli
by 37% after 7 days.57 No life-threatening intracranial or major bleed-
ing was observed, but the sample size was small. For these reasons,
Figure 1 Management of antithrombotic treatment in patients with carotid artery stenosis. DAPT = dual antiplatelet therapy, a daily combination
of aspirin (75–100 mg) and clopidogrel (75 mg); CAS = carotid artery stenting; SAPT = single antiplatelet therapy; TIA = transient ischaemic attack.
aAt the exception of patient at very high bleeding risk.
bDAPT may be used if another indication supersedes that of carotid artery stenting such as acute coronary syndrome or percutaneous
coronary intervention of less than 1 year.
cIn case of recent minor stroke or TIA. A loading dose of aspirin (300 mg) and/or clopidogrel (300/600 mg) is recommended at the
acute phase of stroke/TIA or during CAS.
dStands for as long as it is well tolerated.
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DAPT may be considered within 24 h of a minor ischaemic stroke or
transient ischaemic attack (TIA) and may be continued for 1 month in
patients treated conservatively.58
DAPT is recommended in patients undergoing CAS. Two small RCTs
comparing aspirin alone with DAPT for CAS were terminated prema-
turely due to high rates of stent thrombosis and neurological events in
the aspirin-alone group.59,60 These data were obtained at 30 days. Most
events were procedure related. The optimal duration of DAPT following
CAS is unknown. Recent studies showing late brain lesions on diffusion-
weighted MRI after CAS question whether DAPT beyond the first
month may be required.61 However, potential risks include haemor-
rhagic transformation in patients with recent stroke and intracranial
bleeding in patients at risk of reperfusion injury following revasculariza-
tion. DAPT may be prolonged beyond 1 month after CAS in the pres-
ence of recent (<12 months) MI and low bleeding risk (Figure 1).62
5.2 Antithrombotic therapy in lower
extremity artery disease
Antiplatelet agents are used in patients with LEAD to prevent limb-
related and general CV events. A number of antiplatelet strategies are
available, but their specific indications remain unclear.63 One study
compared clopidogrel with aspirin51 and two studies compared clopi-
dogrel plus aspirin to aspirin alone.64,65 No specific trial addressed the
role of antiplatelet agents in the full spectrum of LEAD (asymptomatic,
IC and CLTI). Also, the Task Force is aware of the premature halting of
the COMPASS trial for ‘overwhelming’ efficacy. The trial compared
rivaroxaban monotherapy (5 mg twice a day) with dual therapy (aspirin
plus rivaroxaban 2.5 mg twice a day) and with aspirin monotherapy in
27 402 patients with CAD or LEAD. As the data were neither pre-
sented nor published at the time of guideline printing, the Task Force
was unable to address these results and their potential clinical conse-
quences. Hence the Task Force will consider the results when they
become available, as well as the option for an update if necessary.
5.2.1 Single antiplatelet therapy
Two trials, one in a general population (with ABI <0.95)66 and
another in diabetic patients (with ABI <1.0)67, found no benefit from
aspirin in subclinical LEAD.
In symptomatic LEAD, the strongest evidence in favour of aspirin to
protect against MACE (combining non-fatal MI and stroke with CV
death) comes from the Antithrombotic Trialists Collaboration.54 In
6200 patients with IC, aspirin significantly reduced MACE vs. controls
(6.4 vs. 7.9%). Another meta-analysis of RCTs comparing aspirin to pla-
cebo in patients with LEAD (symptomatic or asymptomatic) showed a
non-significant reduction in MACE {relative risk [RR] 0.75 [95% confi-
dence interval (CI) 0.48–1.18]}.68 No significant benefit was found
within the individual components except for a reduction in non-fatal
stroke [RR 0.64 (95% CI 0.42–0.99)].68 In a post hoc analysis of the
Clopidogrel versus Aspirin in Patients at Risk of Ischaemic Events
(CAPRIE) trial, at 3 years, clopidogrel was superior to aspirin in the sub-
group of patients with clinical LEAD (n = 6452), with significant reduc-
tions in CV mortality [hazard ratio (HR) 0.76 (95% CI 0.64–0.91)] and
MACE [HR 0.78 (95% CI 0.65–0.93)], with similar benefit in the sub-
group of LEAD patients with diabetes.51 In the randomized Effects of
Ticagrelor and Clopidogrel in Patients with Peripheral Artery Disease
(EUCLID) trial, ticagrelor was compared to clopidogrel in 13 885
patients >_50 years of age with symptomatic LEAD.69 The trial failed to
show any difference regarding MACE [HR 1.02 (95% CI 0.92–1.13)] or
major bleeding [HR 1.10 (95% CI 0.84–1.43)].
5.2.2 Dual and triple antiplatelet therapy
So far, data proving the superiority of DAPT (with clopidogrel) over
aspirin alone to reduce CV events in patients with LEAD are lacking.63
In the subgroup of patients with LEAD enrolled in the CHARISMA trial
(n = 3906), DAPT led to a reduction in MI [HR 0.63 (95% CI
0.42–0.95)], with a neutral effect on all the other vascular events, at the
cost of increased severe, fatal or moderate bleeding [HR 1.99 (95% CI
1.69–2.34)].65 Because of the post hoc nature of this analysis and the
negative results of the overall trial, these findings need confirmation.
Vorapaxar, a protease-activated receptor-1 inhibitor, was tested vs.
placebo on top of standard antiplatelet therapy in secondary preven-
tion in patients with clinical LEAD (n = 3787).70 Vorapaxar did not
reduce the risk of MACE [HR 0.94 (95% CI 0.78–1.14)] but significantly
reduced the risk of acute limb ischaemia [HR 0.58 (95% CI 0.39–0.86)]
and peripheral revascularization [HR 0.84 (95% CI 0.73–0.97)].70 This
benefit was observed irrespective of the underlying mechanism of
acute limb ischaemia, including surgical graft thrombosis and native ves-
sel thrombosis.71 These beneficial effects were counterbalanced by an
increased risk of bleeding [HR 1.62 (95% CI 1.21–2.18)].
5.2.3 Antithrombotic therapy after lower-extremity
bypass grafting
Antiplatelet agents are mostly used after peripheral percutaneous revas-
cularization, while warfarin has a small role (Figure 2). No conclusive
data are yet available for direct oral thrombin and factor Xa inhibitors.72
5.2.3.1 Aspirin vs. placebo
In a meta-analysis of 952 patients, graft patency was significantly improved
with aspirin (with or without dipyridamole) vs. placebo (HR 0.42, P =
0.01).72 Notably, at any of the time points, this effect was not observed
for venous grafts alone but for prosthetic grafts (at 12months: OR 0.19,
P< 0.00001). Amputation, survival and bleeding rates were similar.
5.2.3.2 Aspirin vs. oral anticoagulation
In the Dutch Bypass Oral Anticoagulants or Aspirin Study, no difference
in graft patency was found between aspirin (or aspirin/dipyridamole)
and vitamin K antagonist (VKA) over 2 years of follow-up [HR 0.64
(95% CI 0.25–1.63)].73 There was no difference in mortality [OR 1.02
(95% CI 0.83–1.26)] or amputation [OR 0.99 (95% CI 0.75–1.30)].
Major bleeding risk doubled with VKA [with high target international
normalized ratios (INRs) > 3].73 There were significantly fewer venous
bypass occlusions under VKA vs. aspirin [HR 0.69 (95% CI 0.51–0.94)].
In another study, the addition of warfarin to aspirin failed to show any
improvement in graft patency vs. aspirin alone, with a 2-fold increased
risk of major bleeding.74 DAPT has been compared with VKA plus clo-
pidogrel (n = 341) in femoro-popliteal bypass, with marginal benefit on
graft failure, more bleeding and no effect on MACE.75
5.2.3.3. Aspirin vs. dual antiplatelet therapy
Among the 851 patients with below-the-knee bypass grafting enrolled
in the Clopidogrel and Acetylsalicylic Acid in Bypass Surgery for
Peripheral Arterial disease (CASPAR) randomized controlled trial, no
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was found regarding the occurrence of index graft occlusion or revas-
cularization, above-ankle amputation of the affected limb or death
[HR 0.98 (95% CI 0.78–1.23)].64 In the pre-specified subgroup of
patients with a prosthetic graft, the primary efficacy endpoint was
reduced in DAPT patients vs. aspirin alone [HR 0.65 (95% CI
0.45–0.95)] with a significant interaction according to the type of graft
(venous vs. prosthetic). There was no statistically significant difference
in the incidence of primary events when a venous graft was used [HR
1.25 (95% CI 0.94–1.67)]. Although total bleeding was more frequent
on DAPT [HR 2.65 (95% CI 1.69–4.15)], there was no significant dif-
ference regarding severe or fatal bleeding (2.1 vs. 1.2%).
5.2.4 Antithrombotic drugs after endovascular therapy
for lower extremity artery disease
DAPT is currently recommended for at least 1 month after interven-
tion, irrespective of the stent type (bare metal vs. drug eluting). In the
Zilver PTX randomized trial comparing provisional drug-eluting
stents to bare-metal stents, DAPT was mandated for 2 months.76 In
the IN.PACT SFA trial, half of the patients were on DAPT at 1 year.77
Stenting below-the-knee arteries is often followed by a longer period
of DAPT, but no specific evidence is available. Anticoagulation has
been prospectively tested after percutaneous infra-inguinal revascula-
rization. Vascular patency was not improved, while bleeding was sig-
nificantly increased.78
5.2.5 Patients with lower extremity artery disease and
concomitant coronary artery disease
In patients with CAD, the coexistence of LEAD is associated with a
worse prognosis irrespective of the clinical presentation. It has a
direct impact on the duration and type of antiplatelet therapy regi-
men, in particular when there is a prior history of coronary stenting
or acute coronary syndrome (ACS). The coexistence of LEAD in
patients with CAD may be an argument for prolonged DAPT. The
PROlonging Dual antiplatelet treatment after Grading stent-induced
intimal hYperplasia (PRODIGY) trial tested DAPT duration after
ACS. Prolonged (24 months) vs. short (6 months) DAPT conveyed a
lower risk of the primary efficacy endpoint, a composite of death, MI
or cerebrovascular accidents, in patients with LEAD [HR 0.54 (95%
CI 0.31–0.95)] but not in those without [HR 1.28 (95% CI
0.92–1.77)]. A significant interaction (P = 0.01) suggests specific ben-
efits only in patients with concomitant LEAD.79 In the Prevention of
Figure 2 Antiplatelet therapy in patients with lower extremity artery disease. DAPT = dual antiplatelet therapy; SAPT = single antiplatelet therapy;
VKA = vitamin K antagonist.
ae.g. concomitant AF or mechanical valve prosthesis.
bSAPT should be considered if there is another concomitant atherosclerotic disease (e.g. coronary artery disease).
cDAPT may be considered in patients with recent acute coronary syndrome and/or percutaneous coronary intervention (<1 year),
stenting of the last patent coronary artery, multiple coronary vessel diseasein diabetic patients with incomplete revascularization.
dEvidence is weak and bleeding doubles as compared to SAPT.
eStands for as long as it is well tolerated.
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..Cardiovascular Events in Patients with Prior Heart Attack Using
Ticagrelor Compared to Placebo on a Background of
Aspirin–Thrombolysis in Myocardial Infarction 54 (PEGASUS-TIMI
54) trial, the addition of ticagrelor 90 mg twice a day or 60 mg twice a
day on top of low-dose aspirin in stable patients with prior MI
(1–3 years) was investigated.80 Among patients with known LEAD
(5% of the entire population), ticagrelor (pooled doses) reduced sig-
nificantly the risk of major adverse limb outcomes (acute limb ischae-
mia and peripheral revascularization) [HR 0.65 (95% CI 0.44–0.95)].
In addition, in patients with LEAD, ticagrelor showed the greatest
benefit, with an absolute risk reduction (ARR) of 4.1% [number
needed to treat (NNT) = 25] for MACE and an absolute excess of
major bleeding of 0.12% [number needed to harm (NNH) = 834].81
Therefore, long-term ticagrelor on top of low-dose aspirin may be
considered in LEAD patients with prior MI (<3 years).
DAPT duration in these settings should follow the current guide-
lines.82 In LEAD patients who underwent infra-inguinal percutaneous
revascularization, DAPT may be prolonged beyond 1 month when
there is a prior history (<1 year) of ACS and/or percutaneous coro-
nary intervention (PCI) (Figure 2). Yearly reassessment of DAPT
should be considered according to the patient’s clinical status.
5.3 Antithrombotic therapy in lower
extremity artery disease patients
requiring long-term oral anticoagulant
AF is frequent in patients with LEAD, with a worse outcome as com-
pared to those without AF (see section 12.3).83,84 Although evidence
is scarce to support a specific antithrombotic regimen in patients with
LEAD and an indication for oral anticoagulation (OAC), the first step is
to reassess the indication for OAC. OAC should be continued only if a
compelling indication exists (e.g. paroxysmal, persistent or permanent
AF with a Congestive heart failure, Hypertension, Age >_75 (2 points),
Diabetes mellitus, Stroke or TIA (2 points), Vascular disease, Age
65–74 years, Sex category (CHA2DS2-VASc) score >_2; mechanical
heart valve; recent or a history of recurrent deep venous thrombosis
or pulmonary embolism). Importantly, LEAD accounts for 1 point in
the CHA2DS2-VASC score and can shift the indication for OAC. A
post hoc analysis of the Rivaroxaban Once Daily Oral Direct Factor
Xa Inhibition Compared with Vitamin K Antagonism for Prevention of
Stroke and Embolism Trial in Atrial Fibrillation (ROCKET-AF) trial
reported a significant interaction for major and non-major clinically rel-
evant bleeding in patients with LEAD (n = 839) treated with rivaroxa-
ban vs. warfarin [HR 1.40 (95% CI 1.06–1.86)] compared to patients
Figure 3 Antithrombotic therapy in patients with LEAD requiring oral anticoagulation. ACS = acute coronary syndrome; CAD = coronary artery
disease; CLTI: chronic limb-threatening ischaemia; DAT = dual antithrombotic therapy; LEAD = lower extremity artery disease; NOACs = non-vita-
min K oral anticoagulants; OAC = oral anticoagulation; VKA = vitamin K antagonist.
aDAT may be considered in high ischaemic rick patients defined as prior stent thrombosis, acute limb ischaemia on OAC and concomi-
tant CAD (recent ACS, stenting of the last patent coronary artery, multiple coronary vessel disease in diabetic patients with incomplete
revascularization).
bCompared to the risk for stroke/CLTI due to stent/graft occlusion.
cStands for as long as it is well tolerated.
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.without LEAD [HR 1.03 (95% CI 0.95–1.11); interaction P = 0.037].85
Additional studies are needed.
The duration of combined therapy should be as limited as possible
(1 month), depending on the clinical indication and bleeding risk.82,83
The addition of an antiplatelet treatment may depend on concomi-
tant CAD and the need for LEAD endovascular revascularization.
With the exception of below-the-knee stenting or complex lesions
at very high risk of thrombosis, triple therapy (i.e. aspirin, clopidogrel
and an anticoagulant) is discouraged in this setting. The proposed
treatment algorithm taking into account the management strategy
and bleeding risk is shown in Figure 3. Gastric protection with a
proton pump inhibitor is recommended and the dose intensity of
OAC should be carefully monitored with a target INR of 2.0–2.5 in
patients treated with VKA, with the exception of individuals with
mechanical prosthetic valves in the mitral position. In patients treated
with non-vitamin K oral anticoagulants (NOACs), the lowest dose in
approval studies for stroke prevention should be applied when com-
bined with antiplatelet therapy.83,86
5.4 Antithrombotic therapy after
endovascular therapy in other territories
See Web addenda 5.4.
Recommendations on antithrombotic therapy in patients with peripheral arterial diseases
Recommendations Classa Levelb
Carotid artery disease
In patients with symptomatic carotid stenosis, long-term SAPT is recommended (87). I A
DAPT with aspirin and clopidogrel is recommended for at least 1 month after CAS (60). I B
In patients with asymptomatic >50% carotid artery stenosis, long-term antiplatelet therapy (commonly low-dose aspirin) should be
considered when the bleeding risk is low.c
IIa C
Lower extremities artery disease
Long-term SAPT is recommended in symptomatic patients.51,54,68 I A
Long-term SAPT is recommended in all patients who have undergone revascularization.72 I C
SAPT is recommended after infra-inguinal bypass surgery.72,88,89 I A
In patients requiring antiplatelet therapy, clopidogrel may be preferred over aspirin.51,69 IIb B
Vitamin K antagonists may be considered after autologous vein infra-inguinal bypass.73 IIb B
DAPT with aspirin and clopidogrel for at least 1 month should be considered after infra-inguinal stent implantation. IIa C
DAPT with aspirin and clopidogrel may be considered in below-the-knee bypass with a prosthetic graft.64 IIb B
Because of a lack of proven benefit, antiplatelet therapy is not routinely indicated in patients with isolatedd asymptomatic LEAD.66, 67 III A
Antithrombotic therapy for PADs patients requiring oral anticoagulant
In patients with PADs and AF, OAC:83,90
 is recommended when the CHA2DS2-VASc score is >_ 2 I A
 should be considered in all other patients. IIa B
In patients with PADs who have an indication for OAC (e.g. AF or mechanical prosthetic valve), oral anticoagulants alone should be
considered.91
IIa B
After endovascular revascularization, aspirin or clopidogrel should be considered in addition to OAC for at least 1 month if the bleeding risk is
low compared with the risk of stent/graft occlusion.
IIa C
After endovascular revascularization, OAC alone should be considered if the bleeding risk is high compared with the risk of stent/graft occlusion. IIa C
OAC and SAPT may be considered beyond 1 month in high ischaemic risk patients or when there is another firm indication for long-term SAPT. IIb C
AF = atrial fibrillation; CAS = carotid artery stenosis; CHA2DS2-VASc = Congestive heart failure, Hypertension, Age >_75 (2 points), Diabetes mellitus, Stroke or TIA (2 points), Vascular
disease, Age 65–74 years, Sex category; DAPT = dual antiplatelet therapy; LEAD = lower extremity artery disease; OAC = oral anticoagulation; PADs = peripheral arterial diseases;
SAPT = single antiplatelet therapy.
CHA2DS2-VASc score is calculated as follows: congestive heart failure history (1 point), hypertension (1 point), age >75 years (2 points), diabetes mellitus (1 point), stroke or
TIA or arterial thromboembolic history (1 point), vascular disease history (1 point), age 65–74 years (1 point), sex category (1 point if female).
aClass of recommendation.
bLevel of evidence.
cWith the exception of patients with an indication for long-term OAC.
dWithout any other clinical cardiovascular condition requiring antiplatelet therapy (e.g. coronary artery disease or other multisite artery diseases).
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6. Extracranial carotid and
vertebral artery disease
Key messages
• Of all strokes, 10–15% follow thromboembolism from a 50–99%
internal carotid artery stenosis.
• The majority of recently symptomatic patients will gain maximum
benefit when carotid interventions are performed within 14 days
of symptom onset.
• Given the improved prognosis with BMT, the management of
asymptomatic carotid disease remains controversial. However,
some subgroups of patients may benefit from revascularization.
• Predicting the magnitude of the perioperative risk of stroke can
determine whether carotid endarterectomy or CAS is safer in
individual patients, especially in the early time period after the
onset of symptoms and in patients >70 years of age. After the
perioperative period, late stroke rates after carotid endarterec-
tomy and CAS are similar.
• Vertebral artery stenoses are usually treated medically, unless
recurrent symptoms persist despite BMT.
6.1 Carotid artery disease
6.1.1 Definition
The different presentation modes of cerebrovascular events are detailed
in Web Table 4.92 This chapter primarily deals with stroke secondary to
carotid and vertebral artery disease but not cardioembolism. carotid
artery stenosis refers to a>_ 50% stenosis of the extracranial internal caro-
tid artery (ICA), with stenosis severity estimated using the North
American Symptomatic Carotid Endarterectomy Trial (NASCET)
method (Web Figure 1).93 According to the definitions in major trials,
carotid stenosis is defined as ‘symptomatic’ if associated with symptoms
in the preceding 6months and ‘asymptomatic’ if no prior symptoms can
be identified or when symptoms occurred >6months ago. The current
background information and detailed discussion of the data for the fol-
lowing section of these Guidelines can be found in ESC CardioMed.
6.1.2 Diagnosis
6.1.2.1 Clinical evaluation
The different presentation modes of cerebrovascular events are pre-
sented in the Web addenda 6.1.2.1.
6.1.2.2 Imaging
In patients with TIA/stroke, urgent imaging of the brain and supra-aortic
vessels is mandatory. DUS is usually the first-line carotid imaging modal-
ity to assess extracranial ICA stenoses. It includes Doppler velocity
measurements and ratios for accurate evaluation of stenosis severity.
Multiple criteria should be used for reliable estimation of stenosis.
Further details are presented in a recent consensus document.94
Plaque morphological evaluation using MRI or DUS (echolucency,
intraplaque haemorrhage, surface irregularity) may identify patients
with asymptomatic stenoses at higher risk of ipsilateral ischaemic
stroke. Other markers are silent infarction on CT/MRI and the detec-
tion of spontaneous embolization using transcranial Doppler monitor-
ing.95–97 Combining DUS with transcranial Doppler and/or transcranial
colour-coded DUS enables a more thorough assessment of intracranial
stenoses and an evaluation of impaired cerebrovascular reserve.98
The main advantage of CTA/MRA over DUS is their ability to
image simultaneously from the aortic arch up to the intracranial
circulation as well as brain parenchyma. While CT is more widely
available and differentiates between ischaemic and haemorrhagic
stroke, MRI is more sensitive in detecting brain ischaemia, especially
in the early post-stroke period. CTA offers excellent sensitivity and
specificity for detecting carotid stenosis.99 Severe calcification may
overestimate stenosis severity. MRA does not visualize vascular calci-
fication, an important issue should CAS be considered. In a meta-
analysis, DUS, MRA and CTA were equivalent for detecting signifi-
cant carotid stenosis.99 Intra-arterial DSA, necessary for guiding CAS
but not carotid endarterectomy (CEA), is rarely required for diagnos-
tic purposes and is used only in highly selected situations with dis-
cordant non-invasive imaging results or additional intracranial
vascular disease. In a patient with recent TIA or stroke with 50–99%
ICA stenosis, echocardiography and 24–72-h rhythm monitoring
remains suitable to detect the potential source of cardioembolism,
but this should not delay any carotid intervention.
6.1.3. Treatment
6.1.3.1 Medical therapy
The medical management of patients with carotid disease is detailed
in chapters 4 and 5.
6.1.3.2 Open surgery
6.1.3.2.1 Technical aspects. Details about the technical performance of
CEA (type of anaesthesia, patching, shunting and other details) are
summarized in the Web addenda 6.1.3.2.1.
6.1.3.2.2 Postoperative outcomes. Several studies have identified prog-
nostic factors and markers for an increased risk of stroke after CEA.
See Web addenda 6.1.3.2.2.
Recommendations for imaging of extracranial carotid
arteries
Recommendations Classa Levelb
DUS (as first-line imaging), CTA and/or MRA
are recommended for evaluating the extent
and severity of extracranial carotid stenoses.99
I B
When CAS is being considered, it is
recommended that any DUS study be fol-
lowed by either MRA or CTA to evaluate
the aortic arch as well as the extra- and
intracranial circulation.99
I B
When CEA is considered, it is recom-
mended that the DUS stenosis estimation
be corroborated by either MRA or CTA (or
by a repeat DUS study performed in an
expert vascular laboratory).99
I B
CAS = carotid artery stenting; CEA = carotid endarterectomy; CTA = computed
tomography angiography; DUS = duplex ultrasound; MRA = magnetic resonance
angiography.
aClass of recommendation.
bLevel of evidence.
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6.1.3.3 Endovascular techniques
CAS is a potentially less invasive alternative to CEA, with a low risk of
cranial nerve injury, wound complications and/or neck haematoma,
but it is vulnerable to access complications. CAS offers advantages
over CEA in the presence of a ‘hostile neck’ (previous radiation,
recurrent stenosis), contralateral recurrent laryngeal nerve palsy or
in the case of challenging surgical access [very high ICA lesions, proxi-
mal common carotid artery (CCA) lesions], though not necessarily
with a lower risk of perioperative stroke. Patients at higher risk for
suffering perioperative cardiac complications may benefit from CAS
in order to reduce perioperative MI (more common after CEA).100
In a subgroup analysis from the Carotid Revascularization
Endarterectomy versus Stenting Trial (CREST), the 4-year mortality
was significantly higher [HR 3.40 (95% CI 1.67–6.92)] in patients suf-
fering a perioperative MI.100
6.1.3.3.1 Carotid stenting: technical aspects. 6.1.3.3.1.1 Criteria associated
with increased difficulty for carotid artery stenting
See Web addenda 6.1.3.3.1.1.
6.1.3.3.1.2 Embolic protection devices
The rationale for cerebral protection devices is supported by the
presence of embolic material in distal filters,101 but their use remains
controversial. Using diffusion-weighted MRI, studies have reported
lower rates of cerebral embolization with a proximal embolus pro-
tection device (EPD), but none was powered to address clinical out-
comes.102–106 A meta-analysis of 24 studies observed that EPD use
was associated with a lower risk of perioperative stroke (RR 0.59;
P < 0.001).107 A pooled analysis of RCTs also reported significantly
lower rates of perioperative stroke/death (RR 0.57), favouring
EPD.108 The benefit of EPDs was also evident in a prospective regis-
try of 1455 patients: in those treated with EPD, in-hospital death/
stroke rates were at 2.1% vs. 4.9% in patients treated without EPD
(P = 0.004).109 The best results within RCTs were seen in the CREST
and the Asymptomatic Carotid Trial (ACT-1), where cerebral pro-
tection was mandatory and CAS practitioners were trained in its
use.110 In contrast, the Stent-Protected Angioplasty versus Carotid
Endarterectomy (SPACE) trial observed lower ipsilateral stroke rates
in CAS patients without EPD (6.2%) vs. with EPD (8.3%).111 Given
the lack of high-quality data, the revised recommendation in these
guidelines is based on a broad consensus that protection devices
should be considered when performing CAS.
6.1.3.3.2 Carotid artery stenting: operator experience and outcome.
Evidence suggests that experience plays a role in CAS out-
comes.112,113 See Web addenda 6.1.3.3.2.
6.1.4 Management of carotid artery disease
6.1.4.1 Asymptomatic carotid artery disease
6.1.4.1.1 Open surgery vs. medical therapy. The Asymptomatic Carotid
Atherosclerosis Study (ACAS) and the Asymptomatic Carotid
Surgery Trial (ACST-1) compared CEA with medical therapy in
asymptomatic patients with 60–99% carotid stenosis.114–116 In
ACAS, 5-year rates of ipsilateral stroke/death under CEA vs. medical
therapy were 5.1% vs. 11.0%, respectively (P = 0.0001, NNT = 18).
The 10-year risk of ‘any’ stroke rates were 13.4% vs. 17.9%, respec-
tively (P = 0.009, NNT = 22). ACST-1 reported 5-year rates of any
stroke of 6.4% vs. 11.8%, respectively (P < 0.0001, NNT = 19). Fatal/
disabling stroke rates were 3.5% vs. 6.1%, respectively (P = 0.004,
NNT = 38). In a combined analysis of both trials, CEA conferred less
benefit in women at 5 years.117 At 10 years, however, ACST-1115
reported that females gained a small but significant benefit following
CEA (ARR 5.8%, P = 0.05). However, both trials are now rather
dated. In a meta-analysis of 41 studies, the rate of ipsilateral stroke
was 2.3/100 person-years in studies completing recruitment before
2000, compared with 1.0/100 person-years during the 2000–2010
period (P < 0.001).118 A 60–70% decline in annual stroke rates was
also observed in medically treated patients in both trials over the
recruitment period from 1995 to 2010.114–116,119
Despite the small but significant benefit favouring CEA over medi-
cal therapy, the ARR in stroke was only 4.6% at 10 years, indicating
that 95% of asymptomatic patients ultimately underwent unnecessary
interventions.97,115 There is a need to target revascularization in a
subgroup of patients with clinical and/or imaging features that may
make them higher risk for stroke on BMT97 (Table 4). Pending the
Recommendation on the use of embolic protection
device during carotid stenting
Recommendation Classa Levelb
The use of embolic protection devices
should be considered in patients undergoing
carotid artery stenting.
IIa C
aClass of recommendation.
bLevel of evidence.
Table 4 Features associated with increased risk of
stroke in patients with asymptomatic carotid stenosis
treated medically (for details see Web Table 5
HITS = high intensity transient signal; MRA = magnetic resonance angiography;
TIA = transient ischaemic attack.
aAge is not a predictor of poorer outcome.
bMore than 40 mm2 on digital analysis.
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development of better algorithms for patient selection, the presence
of one or more of these clinical or imaging features might be useful
for selecting patients for revascularization.
Importantly, ACST found no evidence that age >75 years at base-
line was associated with any ipsilateral stroke reduction at 5 or
10 years. Additionally, the stenosis severity cannot be a criterion for
stratifying late stroke risk. In a meta-analysis of 41 studies, ipsilateral
stroke in patients with 50–69% and 70–99% stenosis were at 1.9 and
2.1/100 person-years, respectively (p value).118 Neither the ACAS
nor ACST found any evidence that stenosis severity or contralateral
occlusion increased late stroke risk.114,115,120
6.1.4.1.2 Carotid revascularization: surgery vs. stenting. Five RCTs com-
pared CEA with CAS in ‘average risk for CEA’ asymptomatic patients
(Web Table 6), while SPACE-2 also included a third limb for BMT.
The two biggest RCTs (CREST and ACT-1) requested exclusively
experienced interventionists. In ACT-1, the 2.9% rate of death/stroke
after CAS fell within the 3% accepted risk. Because of the learning
curve associated with CAS, as well as it being performed in small
numbers by multiple specialties,129 there are concerns as to whether
the death/stroke rates reported for CAS in these trials can be repli-
cated in ‘real-world’ practice. While some national CAS registries
have published death/stroke rates within 3%,130,131 others have
reported wide variations in practice. In a review of 19 381 CAS pro-
cedures in a registry, there was a 4-fold variation regarding in-hospital
death/stroke despite adjusting for case mix.129 A systematic review in
large administrative dataset registries (>1.5 million procedures) sug-
gested that 40% of registries reported death/stroke rates after CAS
>3% in asymptomatic patients, while 14% reported death/stroke
rates >5%.132 In some large registries the median annual number of
CAS procedures in asymptomatic patients may only be one or
two,133 which is known to be associated with higher rates of perio-
perative stroke/death.134
The Stenting and Angioplasty with Protection in Patients at High
Risk for Endarterectomy (SAPPHIRE) trial randomized symptomatic
and asymptomatic patients deemed ‘high risk for surgery’ to either
CEA or CAS (using EPDs routinely).135 High surgical risk was defined
as clinically significant cardiac disease, severe pulmonary disease, con-
tralateral ICA occlusion, contralateral recurrent laryngeal nerve
palsy, previous radical neck surgery or radiotherapy, recurrent steno-
sis after CEA and age >80 years. The primary endpoint (30-day
death/stroke/MI and/or death or ipsilateral stroke between 31 days
and 1 year) occurred in 12.2% of CAS patients and 20.1% of CEA
patients (P = 0.053). At 3 years, major ipsilateral stroke (CAS 1.3% vs.
CEA 3.3%), minor ipsilateral stroke (6.1% vs. 3.0%) and repeat revas-
cularization (3.0% vs. 7.1%) were not statistically different.136
However, 71% of SAPPHIRE patients were asymptomatic, in whom
the 30-day rate of death/stroke after CAS was 5.8% vs. 6.1% after
CEA,135 both beyond the recommended 3%. If these procedural risk
levels reflect contemporary practice, most ‘high-risk for surgery’
asymptomatic patients would be better treated medically.
6.1.4.2 Symptomatic carotid artery disease
6.1.4.2.1 Open surgery. In a meta-analysis of all symptomatic patients
randomized within NASCET and the European Carotid Surgery Trial
(ECST), those with a NASCET 0–49% stenosis gained no benefit
from surgery. CEA conferred a 7.8% ARR for stroke at 5 years in
patients with 50–69% stenoses (NNT = 13). The maximum benefit
was seen in patients with 70–99% ICA stenoses, where the ARR for
stroke was 15.6% (NNT = 6).138
A number of clinical/imaging features are associated with an
increased rate of late stroke in symptomatic patients with 50–99%
stenoses if treated medically: increasing age (especially >75 years),
Recommendations for management of asymptomatic
carotid artery disease
Recommendations Classa Levelb
In ‘average surgical risk’ patients with an
asymptomatic 60–99% stenosis, CEA should
be considered in the presence of clinical
and/or more imaging characteristicsc that
may be associated with an increased risk of
late ipsilateral stroke, provided documented
perioperative stroke/death rates are <3%
and the patient’s life expectancy
is > 5 years.116
IIa B
In asymptomatic patients who have been
deemed ‘high risk for CEA’d and who have
an asymptomatic 60–99% stenosis in the
presence of clinical and/or imaging charac-
teristicsc that may be associated with an
increased risk of late ipsilateral stroke, CAS
should be considered, provided docu-
mented perioperative stroke/death rates
are <3% and the patient’s life expectancy
is > 5 years.135,136
IIa B
In ‘average surgical risk’ patients with an
asymptomatic 60–99% stenosis in the pres-
ence of clinical and/or imaging characteris-
ticsd that may be associated with an
increased risk of late ipsilateral stroke, CAS
may be an alternative to CEA provided
documented perioperative stroke/death
rates are <3% and the patient’s life expect-
ancy is > 5 years.110,129,132,137
IIb B
BP = blood pressure, CAS = carotid artery stenting, CEA = carotid
endarterectomy.
aClass of recommendation.
bLevel of evidence.
cSee Table 4 and Web Table 5.
dAge >80 years, clinically significant cardiac disease, severe pulmonary disease,
contralateral internal carotid artery occlusion, contralateral recurrent laryngeal
nerve palsy, previous radical neck surgery or radiotherapy and recurrent stenosis
after CEA.
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..symptoms within 14 days, male sex, hemispheric (vs. retinal) symp-
toms, cortical (vs. lacunar) stroke, increasing number of medical
comorbidities, irregular stenoses, increasing stenosis severity, con-
tralateral occlusion, tandem intracranial stenoses and a failure to
recruit intracranial collaterals.139
A meta-analysis from ECST and NASCET showed that when CEA
was performed within 14 days in patients with 50–69% stenoses, the
ARR for stroke at 5 years was 14.8% (NNT = 7). The ARR declined
to 3.3% when the delay was 2–4 weeks (NNT = 30) and 2.5% when
the delay was 4–12 weeks (NNT = 40). Beyond 12 weeks, no strokes
were prevented by CEA. In patients with 70–99% stenoses who
underwent CEA within 14 days, the ARR for stroke at 5 years was
23.0% (NNT = 4), falling to 15.9% where delays were 2–4 weeks
(NNT = 6) and 7.9% for delays of 4–12 weeks (NNT = 13).
When performed beyond 12 weeks, the ARR was 7.4% at 5 years
(NNT = 14).117,139 Women appeared to gain almost no benefit from
CEA when performed beyond 4 weeks.117,138,139
The risk of stroke is high within the first days after TIA. The early
risk of stroke in patients with 50–99% ICA stenoses ranged from 5 to
8% within 48 h after TIA, up to 17% by 72 h, 8–22% by 7 days and
11–25% at 14 days.139
There is controversy over whether CEA can be performed safely
within the first 48 h after symptom onset. The Swedish Registry (n =
2596 CEAs) reported that when CEA was performed within the first
48 h, 11.5% died or suffered a stroke as compared with a procedural
risk of < 5% when done any time afterwards.140 In contrast, the UK
national audit (n = 23 235 CEAs) reported that when CEA was per-
formed within 48 h, the rate of death/stroke was much lower than
observed in Sweden (3.7%). Thereafter, procedural risks were
<2%.141 A similarly low risk of death/stroke (3.0%) was observed in
Figure 4 Management of extracranial carotid artery disease. BMT = best medical therapy; CAS = carotid artery stenting; CEA = carotid endarter-
ectomy; CTA = computed tomography angiography; MRA = magnetic resonance angiography; TIA = transient ischaemic attack.
aWith post-stenotic internal carotid artery narrowed to the point of near occlusion.
bSee Table 4.
cAge > 80 years, clinically significant cardiac disease, severe pulmonary disease, contralateral internal carotid artery occlusion, contrala-
teral recurrent laryngeal nerve palsy, previous radical neck surgery or radiotherapy and recurrent stenosis after CEA.
ESC Guidelines 781
D
ow
nloaded from
 https://academ
ic.oup.com
/eurheartj/article-abstract/39/9/763/4095038 by Theology Library, U
niversity of H
elsinki user on 10 M
ay 2019
..
..
..
..
..
..
..
..
..
..
..
..
..Germany when CEA was performed in < 48 h.142 These registries
suggest that CEA can be performed safely in the first 7 days after TIA/
minor stroke onset. However, not all patients will benefit from
urgent revascularization. There may be an increased risk of haemor-
rhagic transformation within a recent area of infarction. Higher-risk
patients include those with acute carotid occlusion or a persisting
major neurological deficit, an area of middle cerebral artery infarction
exceeding one-third, evidence of pre-existing parenchymal haemor-
rhage and evidence of impaired consciousness.
A meta-analysis of five randomized trials has shown that emer-
gency endovascular treatment of acute ischaemic stroke (mechanical
thrombectomy and/or intra-arterial thrombolysis) was associated
with 2.22 times greater odds of a better functional outcome com-
pared with those randomized to medical management. Endovascular
therapy was not associated with a modified risk of symptomatic intra-
cerebral hemorrhage.143 In the MultiCenter Randomized Clinical
Trial of Ischemic Stroke in the Netherlands (MR CLEAN), 13% of
patients underwent simultaneous CAS, but no data were specifically
provided on its procedural risk.144
6.1.4.2.2 Endovascular therapy vs. open surgery. The 30-day outcomes in
four large contemporary RCTs comparing CEA with CAS are
detailed in Web Table 7. Overall, the risk of ‘any stroke’ and ‘death/
stroke’ was 50% higher following CAS, primarily because CAS was
associated with a significantly higher rate of minor stroke. Although
the CREST reported that the majority of minor perioperative strokes
resolved by 6 months,145,146 it was also reported that any type of
perioperative stroke was associated with a 3-fold poorer long-term
survival,146 similar to the poorer 4-year survival observed in patients
suffering a perioperative MI.100
In a meta-analysis of 13 RCTs (80% involving symptomatic
patients), CAS was associated with an increased risk of any stroke
but a decreased risk of perioperative MI and cranial nerve injury.147 In
a Cochrane review (16 RCTs, 7572 patients), CAS was associated
with higher periprocedural death/stroke, especially in patients
>70 years of age, but with significantly lower risks for MI, cranial
nerve injury and haematoma.148
In an individual-based meta-analysis, patients undergoing CEA
within 7 days of symptoms had a 2.8% risk of stroke/death compared
with 9.4% after CAS. Patients undergoing CEA 8–14 days after symp-
tom onset had a 3.4% risk of stroke/death compared with 8.6% after
CAS.149 In the CREST, CAS performed within 14 days of symptom
onset incurred a 5.6% rate of death/stroke compared with 2.6% after
CEA. In symptomatic patients undergoing an intervention at 15–60
days, CAS was associated with a 6.1% risk of death/stroke compared
with 2.3% after CEA.150
A meta-analysis151 of 30-day death/stroke rates after CEA and
CAS involving symptomatic patients randomized within the CREST,
Endarterectomy vs Stenting in Patients with Symptomatic Severe
Carotid Stenosis (EVA-3S), SPACE and International Carotid
Stenting Study (ICSS) (Web Table 8) reported significantly higher
rates of perioperative stroke in patients >70 years of age undergoing
CAS. In contrast, age had little effect on CEA outcomes. The increase
in perioperative stroke in elderly CAS patients may be due to a
greater burden of aortic arch disease. Beyond the 30-day periopera-
tive period, long-term data suggest that outcomes after CAS are
almost identical to those after CEA.152,153 Henceforth the predicted
magnitude of the 30-day risk will largely determine whether CEA or
CAS is preferable in individual patients. Importantly, in a recent sys-
tematic review, 72% of registries reported 30-day death/stroke rates
after CAS exceeding the 6% recommended risk threshold in patients
with symptomatic ICA stenosis.132
An algorithm for managing TIA/minor stroke patients with carotid
disease is presented in Figure 4.
6.2 Vertebral artery disease
6.2.1 Definition and natural history
Up to 20% of ischaemic cerebrovascular events involving the poste-
rior circulation are related to vertebral artery disease.156 For further
details see Web addenda 6.2.1.
Recommendations on revascularization in patients with
symptomatic carotid disease*
Recommendations Classa Levelb
CEA is recommended in symptomatic
patients with 70–99% carotid stenoses, pro-
vided the documented procedural death/
stroke rate is < 6%.138,147
I A
CEA should be considered in symptomatic
patients with 50–69% carotid stenoses, pro-
vided the documented procedural death/
stroke rate is < 6%.138,147
IIa A
In recently symptomatic patients with a
50–99% stenosis who present with adverse
anatomical features or medical comorbid-
ities that are considered to make them ‘high
risk for CEA’, CAS should be considered,
provided the documented procedural
death/stroke rate is < 6%.135,145,152
IIa B
When revascularization is indicated in ‘aver-
age surgical risk’ patients with symptomatic
carotid disease, CAS may be considered as
an alternative to surgery, provided the
documented procedural death/stroke rate
is < 6%.152,153
IIb B
When decided, it is recommended to per-
form revascularization of symptomatic
50–99% carotid stenoses as soon as possi-
ble, preferably within 14 days of symptom
onset.138,154,155
I A
Revascularization is not recommended in
patients with a < 50% carotid stenosis.138
III A
*Stroke or TIA occurring within 6 months.
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6.2.2 Imaging
CTA/MRA have a higher sensitivity (94%) and specificity (95%) than
DUS (sensitivity 70%).157 Vertebral ostial stenoses are overestimated
by MRA,158 while CTA underestimates the degree and prevalence of
ostial vertebral artery stenoses. Despite these limitations, DSA is
rarely required for diagnostic purposes. However, DSA may be neces-
sary in patients with symptomatic vertebral artery disease who are
potentially candidates for revascularization. In patients with known
vertebral artery stenoses, it is reasonable to use DUS to assess steno-
sis progression and to follow patients after revascularization therapies.
6.2.3 Management of vertebral artery disease
Although no prospective RCTs have evaluated different drug thera-
pies in patients with vertebral artery disease, aspirin (or clopidogrel if
aspirin is not tolerated) and statins are recommended irrespective of
symptoms (see chapters 4 and 5). Most patients with asymptomatic
vertebral artery disease do not require any revascularization.
In patients with ischaemic events despite antiplatelet therapy,
revascularization may be considered. Surgery of extracranial verte-
bral stenoses (with transposition to CCA, trans-subclavian vertebral
endarterectomy, distal venous bypass) can be performed with low
stroke/death rates in experienced surgical teams.159,160 However, in
centres with limited expertise with complex vertebral artery recon-
structions, open surgery has been mostly replaced by endovascular
interventions. A systematic review identified 993 patients who were
mostly symptomatic, 72% of whom had ostial vertebral stenoses.
Overall, 980 were treated with stent implantation with a technical
success rate of 99.3% and a 30-day stroke rate of 1.1%. At 24 months,
1.1% had suffered a recurrent vertebrobasilar stroke. Restenosis
rates at 24 months were 11% in patients treated with drug-eluting
stents and 30% if bare-metal stents were used.161
The Vertebral Artery Stenting Trial (VAST)162 randomized
patients with vertebrobasilar symptoms within the preceding 30 days
and an extra- or intracranial vertebral artery stenosis >50% to stent-
ing plus BMT (n = 57) or BMT alone (n = 58). The VAST was sus-
pended after recruiting 115 patients, because of regulatory issues.
Thirty-day vertebrobasilar stroke or death occurred in 5% of patients
randomized to stenting and 2% in the medical arm. At 3 years, 12% of
stented patients had recurrent vertebrobasilar stroke compared with
7% in the medical arm. These results do not support routine endo-
vascular interventions for symptomatic vertebral artery stenoses
unless symptoms recur despite optimal medical therapy.
7. Upper extremity artery disease
Key messages
• Upper extremity artery disease due to atherosclerosis is mostly
situated at the level of the brachiocephalic trunk and the subcla-
vian and axillary arteries.
• When clinically suspected, it can be assessed by DUS, CTA or
MRA.
• In most asymptomatic patients, medical treatment is the option
of choice.
• Revascularization can be proposed for severe/disabling symptoms,
bilateral stenosis or stenosis with ipsilateral arteriovenous fistula for
dialysis or in patients planned for coronary artery bypass grafting or
those already operated on with ipsilateral internal mammary artery
grafted to coronary arteries with evidence of myocardial ischaemia.
• When revascularization is considered, both endovascular and
open surgical options can be proposed according to lesion char-
acteristics and the patient’s risk.
General data, natural history and clinical examination are presented
in Web addenda 7.1, 7.2 and 7.3 and Web Table 9. The current back-
ground information and detailed discussion of the data for the follow-
ing section of these Guidelines can be found in ESC CardioMed.
7.4 Diagnostic methods
7.4.1 Duplex ultrasound
Doppler assessment of subclavian arteries enables the detection of high-
velocity flows indicating >50% stenosis. Due to the proximal location of
subclavian lesions, it is sometimes challenging to differentiate high-grade
ostial stenosis from complete occlusion. Monophasic post-stenotic flow
and altered flow in the ipsilateral vertebral artery are common in the case
of> 70% proximal subclavian stenosis. When subclavian steal syndrome
is suspected, flow reversal should be assessed in the ipsilateral extracranial
vertebral artery by hyperaemia testing. Severe stenosis or occlusion of
the right brachiocephalic trunk is associated with reduced flow velocities
in the ipsilateral subclavian artery and the CCA. Abnormal or doubtful
duplex ultrasound should lead to anatomic imaging (CTA or MRA).
7.4.2 Computed tomography angiography
CTA is an excellent imaging tool for supra-aortic lesions. It can also
provide extravascular information, especially when thoracic outlet
syndrome is a differential diagnosis.
7.4.3 Magnetic resonance angiography
MRA provides both functional and morphological information useful
to distinguish anterograde from retrograde perfusion and to estimate
stenosis severity.
7.4.4 Digital subtraction angiography
Although considered as the gold standard imaging method, DSA is
being increasingly replaced by other imaging modalities. Its main use
is in combination with endovascular therapy.
7.4.5 Positron emission tomography
Positron emission tomography is useful for the diagnosis of arteritis
(Takayasu disease, giant cell arteritis) but not for assessment of athe-
rosclerotic lesions in clinical practice.
Recommendations for management of vertebral artery
stenoses
Recommendations Classa Levelb
In patients with symptomatic extracranial ver-
tebral artery stenoses, revascularization may
be considered for lesions >_50% in patients
with recurrent ischaemic events despite opti-
mal medical management.159,160,162
IIb B
Revascularization of asymptomatic vertebral
artery stenosis is not indicated, irrespective of
the degree of severity.
III C
aClass of recommendation.
bLevel of evidence.
ESC Guidelines 783
D
ow
nloaded from
 https://academ
ic.oup.com
/eurheartj/article-abstract/39/9/763/4095038 by Theology Library, U
niversity of H
elsinki user on 10 M
ay 2019
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
.
7.5 Treatment
Risk factor control and BMT are recommended in all patients with
symptomatic upper extremity artery disease (UEAD) to reduce CV
risk.163 Revascularization is indicated in symptomatic patients with
TIA/stroke, coronary subclavian steal syndrome, ipsilateral haemo-
dialysis access dysfunction or impaired quality of life (QOL).
Revascularization should be considered in asymptomatic patients
with planned coronary artery bypass grafting (CABG) using the inter-
nal mammary artery, those with ipsilateral haemodialysis access, as
well as asymptomatic patients with significant bilateral subclavian
stenosis/occlusion for adequate BP surveillance. For revasculariza-
tion, both endovascular and surgical procedures are available. There
are no RCTs comparing endovascular vs. open repair. The risk of
severe complications, including vertebrobasilar stroke, is low with
both approaches. The post-procedural stroke rate is reported at
2.6% for endovascular therapy164 and 0.9–2.4% after open
surgery.164–166
7.5.1 Endovascular treatment
Percutaneous angioplasty for subclavian arterial stenosis is often
used with stenting. There is no conclusive evidence to determine
whether stenting is more effective than balloon angioplasty.167 In a
systematic review (544 patients) comparing both options, stenting
was superior to angioplasty alone, with a higher patency rate at
1 year indicated by the absence of events.168 Technical success of
endovascular therapy is 100% when treating stenosis and 80–95%
when treating occlusions. Similar results were reported for endo-
vascular therapy of the innominate artery.169 In heavily calcified
ostial lesions, in addition to an easier placement, balloon-
expandable stents give more radial force than nitinol stents. Mid-
term patency (>_24 months) following subclavian endovascular
therapy is 70–85%.170
7.5.2 Open surgery
An endovascular approach is often the default strategy. However,
in selected patients with low operative risk, with subclavian artery
occlusion or after endovascular therapy failure, surgical
subclavian–carotid transposition is safe with good long-term
patency results (5-year patency 96%).166 Carotid–subclavian
bypass surgery with a prosthetic graft showed long-term benefit
with low operative mortality and morbidity rates, especially in
patients with extensive disease or re-occlusion after stenting (5-
year patency 97%).171 Other options are extrathoracic extra-
anatomic bypass procedures (axillo-axillary, carotid–axillary or
carotid–carotid bypass).172,173 The transthoracic approach is an
option in patients with multivessel disease involving the aortic arch
and several supra-aortic vessels.165
7.5.3 Medical therapy
In symptomatic patients with contraindications for endovascular
therapy or open surgery, prostanoid infusion or thoracic sympathec-
tomy may be considered.174
8. Mesenteric artery disease
Key messages
• Mesenteric artery disease, acute or chronic, is underdiagnosed
and highly lethal.
• The prerequisite of diagnosis is clinical suspicion, followed by
imaging.
• In many cases, endovascular surgery should be considered, since
a less invasive option is preferred in these often frail patients.
• In chronic mesenteric disease, open surgery still has an advantage
of better durability in patients with long expected survival.
• In acute embolic occlusion, open and endovascular surgery seem
to have similar success rates.
This section covers acute and chronic occlusion of the
mesenteric arteries. Chronic mesenteric artery disease is related to athe-
rosclerosis as well as non-atherosclerotic conditions. For further informa-
tion refer to the recently published ESVS Guidelines.175 The current
background information and detailed discussion of the data for the fol-
lowing section of these Guidelines can be found in ESC CardioMed.
Recommendations on the management of subclavian
artery stenosis
Recommendations Classa Levelb
In symptomatic patients with subclavian artery
stenosis/occlusion, revascularization should be
considered.
IIa C
In symptomatic patients with a stenotic/
occluded subclavian artery, both revasculariza-
tion options (stenting or surgery) should be
considered and discussed case by case accord-
ing to the lesion characteristics and patient’s
risk.
IIa C
In asymptomatic subclavian artery stenosis, revascularization:
 should be considered in the case of proximal
stenosis in patients undergoing CABG using
the ipsilateral internal mammary artery
IIa C
 should be considered in the case of proxi-
mal stenosis in patients who already have
the ipsilateral internal mammary artery
grafted to coronary arteries with evidence
of myocardial ischaemia
IIa C
 should be considered in the case of subcla-
vian artery stenosis and ipsilateral arterio-
venous fistula for dialysis
IIa C
 may be considered in the case of bilateral
stenosis in order to be able to monitor
blood pressure accurately.
IIb C
CABG = coronary artery bypass grafting.
aClass of recommendation.
bLevel of evidence.
784 ESC Guidelines
D
ow
nloaded from
 https://academ
ic.oup.com
/eurheartj/article-abstract/39/9/763/4095038 by Theology Library, U
niversity of H
elsinki user on 10 M
ay 2019
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
.
8.1 Acute mesenteric ischaemia
8.1.1 Diagnosis
Acute thromboembolic occlusion affects mostly the superior mesen-
teric artery. Due to the extensive collaterals in the mesenteric circu-
lation, the coeliac trunk or the inferior mesenteric artery, occlusion
leads infrequently to intestinal infarction. In most population studies,
acute mesenteric ischaemia is more often related to embolism than
to thrombotic occlusion. Outcome is very time sensitive and depend-
ent on clinical suspicion. In almost 80% of cases, acute embolic occlu-
sion of the superior mesenteric artery is associated with the
following clinical triad: (i) severe abdominal pain with minimal findings
at examination, (ii) bowel emptying (often both vomiting and diar-
rhoea) and (iii) the presence of a source of embolus (e.g. AF).
Embolism also often affects other localizations, which is helpful for
orienting the diagnosis.
Acute thrombotic occlusion of the superior mesenteric artery is
most often a result of an ostial proximal stenosis or occlusion, with
or without general circulatory factors such as dehydration, low car-
diac output or hypercoagulability. The patients often have previous
symptoms of chronic mesenteric ischaemia (CMI), other atheroscler-
otic manifestations and a smoking history.
Although D-dimer is highly sensitive, it lacks specificity. There are
no other reliable plasma markers for acute mesenteric
ischaemia.176–178 In a meta-analysis, the pooled sensitivity for D-dimer
was 96%, with a specificity of 40%.179 Lactate is metabolized effectively
by the liver, explaining why it does not serve as an early warning.
Lactate is elevated only after bowel gangrene has developed.179
Plain abdominal X-ray is not specific. If normal, it does not exclude
the diagnosis. High-resolution CTA is a major breakthrough for the
timely diagnosis of acute mesenteric ischaemia. It should be per-
formed in arterial and venous phases, with 1 mm slices. The diagnos-
tic accuracy for CTA in diagnosing acute superior mesenteric artery
occlusion is excellent. In a meta-analysis the pooled estimated sensi-
tivity was 94% and the specificity was 95%. Asking the radiologist spe-
cifically about occlusion of the mesenteric arteries improves
diagnostic accuracy.180 Elevated creatinine levels are common but
should not contraindicate CTA in the case of clinical suspicion. CT
examination of the bowel (venous phase) may show wall thickening,
dilatation, intestinal pneumatosis, portal venous air, mesenteric
oedema or ascites. There is no role for ultrasound or invasive angiog-
raphy in diagnosing acute mesenteric ischaemia. MRA is seldom avail-
able outside of office hours, explaining why its diagnostic accuracy
has not been investigated in this setting.
8.1.2 Treatment
Most patients with an acute occlusion of the superior mesenteric
artery require immediate revascularization to survive. Approximately
20–30% can survive with bowel resection only, especially with distal
embolism.181 In other cases, revascularization must be attempted.
Whether revascularization or bowel inspection (with possible resec-
tion) should be performed first is controversial. Data suggest that
revascularization should be attempted first, unless there is serious
peritonitis and septic shock.175
Another controversy is whether open surgery or endovascular
therapy of the occluded superior mesenteric artery should be
attempted first.182–185 Hybrid intervention is an alternative, with
retrograde operative mesenteric stenting, where the superior mes-
enteric artery is punctured in the open abdomen, followed by stent-
ing.186 In the absence of RCTs, evidence is based on prospective
registries.182,184,187,188 In the case of embolic occlusion, open and
endovascular revascularizations seem to do equally well, whereas
with thrombotic occlusion, endovascular therapy is associated with
lower mortality and bowel resection rates. The principles of damage
control surgery189 are important to follow when treating these frail
patients. This concept focuses on saving life by restoring normal phys-
iology as quickly as possible, thus avoiding unnecessary time-
consuming procedures.189 Although laparotomy is not mandatory
after endovascular therapy in these patients with acute bowel ischae-
mia, it is often necessary to inspect the bowel. In this setting, second-
look laparotomy is also indicated after open revascularization.184,190
Intra-arterial catheter thrombolysis of the superior mesenteric artery
has been reported with good results. Severe bleeding complications
were uncommon, except when intestinal mucosal gangrene was
present.191
8.2 Chronic mesenteric artery disease
Chronic mesenteric artery disease includes stenosis or chronic occlu-
sion of the coeliac trunk or the mesenteric arteries. Its prevalence
increases with age, especially in the presence of other atherosclerotic
diseases and abdominal aortic aneurysms (AAAs). In patients with an
AAA and LEAD, significant stenosis (mostly asymptomatic) of at least
one of the three arteries was detected in 40% and 27%,
respectively.192
Recommendations on the management of acute mesen-
teric ischaemia
Recommendations Classa Levelb
Diagnosis
In patients with suspected acute mesenteric
ischaemia, urgent CTA is recommended.179
I C
In patients with suspicion of acute mesen-
teric ischaemia, the measurement of D-
dimer should be considered to rule out the
diagnosis.177–179
IIa B
Treatment
In patients with acute thrombotic occlusion
of the superior mesenteric artery, endovas-
cular therapy should be considered as first-
line therapy for
revascularization.182,184,187,188
IIa B
In patients with acute embolic occlusion of
the superior mesenteric artery, both endo-
vascular and open surgery therapy should
be considered.182,184,187,188
IIa B
CTA = computed tomography angiography.
aClass of recommendation.
bLevel of evidence.
ESC Guidelines 785
D
ow
nloaded from
 https://academ
ic.oup.com
/eurheartj/article-abstract/39/9/763/4095038 by Theology Library, U
niversity of H
elsinki user on 10 M
ay 2019
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..8.2.1 Diagnosis
8.2.1.1 Clinical examination
The classic symptoms of CMI are postprandial abdominal pain, weight
loss, diarrhoea or constipation. To avoid pain, the patient suffers
from food aversion, although appetite is not affected (in contrast to
patients with malignancies). As with acute mesenteric ischaemia, clini-
cal suspicion is the key for an early diagnosis and may be lifesaving.
Abdominal examination may reveal a bruit. Non-specific laboratory
findings include anaemia, leucopenia, electrolyte abnormalities and
hypoalbuminaemia secondary to malnutrition.
8.2.1.2 Imaging
DUS is often the imaging tool of first choice. This investigation
requires great skill and should be performed in specialized centres.
Diagnostic criteria have been suggested, although without consen-
sus.193,194 When a decision to treat CMI is made, an anatomical map-
ping of the lesions is needed, mostly using CTA. There is no study
comparing CTA with MRA or DSA, the latter offering the advantages
of mapping the flow and enabling post-stenotic pressure
measurements.
8.2.1.3 Functional assessments
See Web addenda 8.2.1.3.
8.2.2 Treatment
There is no indication for prophylactic revascularization in patients
with asymptomatic disease. In symptomatic CMI, it is not recom-
mended to delay revascularization in order to improve the nutritional
status. Delayed revascularization has been associated with clinical
deterioration, bowel infarction and sepsis from catheter-related
complications.195 The number of mesenteric revascularizations has
increased 10-fold over the last decade as the result of increased rec-
ognition and imaging and the use of endovascular therapy as a less
invasive treatment.188 In most centres, angioplasty and stenting have
become the first option, reserving open surgery for patients with
failed endovascular therapy. Data from the USA show lower postop-
erative mortality after endovascular therapy [OR 0.20 (95% CI
0.17–0.24)].188,196 Open mesenteric bypass, however, offers
improved patency, lower re-intervention rates and better freedom
from recurrent symptoms.188,197 In the absence of RCTs it is not pos-
sible to issue a recommendation favouring open surgery or endovas-
cular therapy as first-line therapy. Both alternatives should be
discussed case by case by a multidisciplinary team.
Another controversy is whether one or two vessels (superior
mesenteric and/or coeliac artery) should be treated. Two retrospec-
tive studies showed a non-significant trend towards lower recurrence
rates with two-vessel stenting.198,199 Another study reported similar
recurrence rates at 2 years.200 Balloon angioplasty has been replaced
by primary stenting in most centres. Regarding the choice between
bare-metal or covered stents to treat superior mesenteric artery
stenosis, in one non-randomized study of 225 patients,201 covered
stents were associated with lower restenosis and symptom recur-
rence rates and fewer re-interventions (10% vs. 50%).
Although endovascular therapy has been increasingly used, open
surgery is still indicated in the following situations: after failed endo-
vascular therapy without possibility for repeat endovascular therapy;
extensive occlusion, calcifications or other technical difficulties; or
young patients with non-atherosclerotic lesions due to vasculitis or
mid-aortic syndrome. Several different surgical techniques are
described with no proof for the superiority of any of them.
8.3 Secondary prevention
Following acute mesenteric arterial occlusion, lifelong medical treat-
ment should be considered, including lifestyle changes and BMT for
atherosclerosis (see chapter 4). After embolic occlusion, treatment
of the source of embolus and/or lifelong anticoagulation therapy
should be considered.202 After treatment of CMI, antiplatelet therapy
is indicated.1 The potential benefit of DAPT is unknown.
9. Renal artery disease
Key messages
• Atherosclerotic renal artery disease (RAD) is the most common
cause of ‘renovascular hypertension’.
• In clinical situations with high suspicion, the use of DUS, usually
as first-line imaging, followed by MRA and/or CTA, is recom-
mended for the establishment of a RAD diagnosis.
• Renal revascularization does not generally improve blood pres-
sure, renal or CV outcomes in patients with atherosclerotic
RAD.
• With few exceptions, medical therapy with antihypertensive
agents, antiplatelet drugs and statins remains the cornerstone for
management of patients with RAD.
Recommendations for management of chronic mesen-
teric artery disease
Recommendations Classa Levelb
Diagnosis
In patients with suspected CMI, DUS is rec-
ommended as the first-line
examination.193,194
I C
In patients with suspected CMI, occlusive
disease of a single mesenteric artery makes
the diagnosis unlikely and a careful search
for alternative causes should be
considered.192,203
IIa C
Treatment
In patients with symptomatic multivessel
CMI, revascularization is
recommended.192,195
I C
In patients with symptomatic multivessel
CMI, it is not recommended to delay revas-
cularization in order to improve the nutri-
tional status.192,195
III C
CMI = chronic mesenteric ischaemia; DUS = duplex ultrasound.
aClass of recommendation.
bLevel of evidence.
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9.1 Introduction
RAD is generally considered when renal artery stenosis (RAS) is >_ 60%,
although additional functional assessment by haemodynamic criteria is
advisable. The prevalence of RAD increases with advancing age and is
mostly related to atherosclerosis. It is associated with male gender,
hypertension, smoking, diabetes mellitus, CKD, aorto-iliac occlusive dis-
ease and CAD.204 It may be present in 5–10% of the general population,
with a higher prevalence in high-risk populations.205 Approximately 20%
have bilateral disease or a single functioning kidney may be affected. Less
frequent causes of RAD are fibromuscular dysplasia (FMD)206 and
arteritis. The former is the most frequent cause of RAD in young hyper-
tensive patients (especially in women). The current background infor-
mation and detailed discussion of the data for the following section of
these Guidelines can be found in ESC CardioMed.
9.2 Clinical presentation
Clinical signs include resistant hypertension, unexplained renal failure
and, uncommonly, flash pulmonary oedema (Table 5). RAD promotes
hypertension and subsequent CV disease, while atherosclerotic disease
may in turn cause RAD. The filtration capacity loss in the ischaemic kid-
ney may be due to either hypoperfusion or recurrent micro-embolism.
Renal hypoperfusion causes a BP increase secondary to activation of the
sympathetic nervous system and the renin–angiotensin–aldosterone
system (RAAS), which may be important for the risk of CV complica-
tions.207 With unilateral RAS, the contralateral kidney increases sodium
excretion and there is no sodium retention or volume overload. In
patients with severe bilateral RAS or unilateral RAS in a single function-
ing kidney, renal failure and flash pulmonary oedema can occur.208
9.3 Natural history
See Web addenda 9.3.
9.4 Diagnostic strategy
Patients with a clinical suspicion of RAS (Table 5) should undergo a
diagnostic evaluation including physical examination, exclusion of
other potential causes of secondary hypertension and ambulatory
(or home) BP measurement.
DUS is the first-line imaging modality to screen for significant
(>_60%) stenosis,205,207,209,210 although it may overestimate the
degree of stenosis. It can be repeated to assess stenosis progression
and its haemodynamic consequences (e.g. flow velocity and vascular
resistance). Peak systolic velocity in the main renal artery shows the
best sensitivity (85%) and specificity (92%) to identify angiographically
significant stenoses.211 Thus criteria other than peak systolic velocity
should be used to support the diagnosis.210,211 The renal resistive
index (RRI) may help to identify more severe RAS and provide addi-
tional information on patient response to intervention.207,210 Further
information regarding the RRI is available in Web addenda 9.4. Renal
DUS requires experience and may be difficult in overweight subjects.
Other limitations include failure to visualize the entire renal artery
and missing the highest peak systolic velocity tracing. Accessory renal
arteries may be missed.
Multidetector CTA and MRA (with or without gadolinium)
show equally high sensitivities (64–100% and 94–97%) and specific-
ities (92–98% and 85–93%) for detection of significant RAS.212,213
CTA provides higher spatial resolution, but usual limitations should
always be considered. Gadolinium-enhanced MRA provides excel-
lent characterization of renal arteries, the surrounding vessels,
renal mass and even renal excretion function. It tends to overesti-
mate the stenosis severity. It is less useful in patients with renal
artery stents, because of artefacts. DSA remains the gold standard
for the diagnosis of RAS.209,212 Since the correlation between the
angiographic stenosis and the haemodynamic impact is poor, a
major advantage of DSA is the possibility to measure the pressure
gradient across the lesion, which is especially useful for moderate
stenosis. A systolic pressure gradient >20 mmHg or a resting pres-
sure ratio distal to the stenosis <0.90 is considered to confirm sig-
nificant stenosis in symptomatic patients.214 Renal artery fractional
flow reserve measured during maximum hyperaemia induced by
papaverine, dopamine or acetylcholine is an alternative method to
assess the stenosis severity, which might predict the clinical
response to intervention.207 Due to the potential risks with inva-
sive procedures, angiography is generally limited to visualization
and quantification of the stenosis before vascular intervention. It is
also indicated when clinical suspicion is high and the results of non-
invasive examinations are inconclusive.205,212 Renal scintigraphy,
plasma renin measurements before and after ACEI provocation
and venous renin measurements are no longer considered for the
diagnosis of atherosclerotic RAD.204,205
Table 5 Clinical situations raising suspicion for renal
artery disease
CKD = chronic kidney disease; RAAS = renin-angiotensin-aldosterone system.
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9.5 Prognosis
Life expectancy is reduced in patients with RAD without end-
stage CKD, as they mostly die from an acute CV event.205,216
Patients who progress to end-stage CKD have even higher mortality
rates.217
9.6 Treatment
9.6.1 Medical therapy
Risk assessment, lifestyle management and medical treatment should
follow current ESC guidelines.25,41,218 Most antihypertensive drugs
(ACEIs, ARBs, calcium channel blockers, beta-blockers and diuretics)
are effective for treating hypertension and may lead to slowing of the
progression of renal disease.219,220 Most patients with significant RAS
tolerate ACEIs or ARBs without difficulty. In large observational stud-
ies, ACEIs and ARBs have shown benefits in reducing mortality and
morbidity in patients with RAD.220–222 However, these drugs can
reduce glomerular capillary hydrostatic pressure enough to cause a
transient decrease in glomerular filtration rate and raise serum creati-
nine, warranting caution and close follow-up. These drugs may be
introduced in the case of bilateral RAS and when the lesion affects a
single functioning kidney, provided that the patients are very carefully
monitored.219,221 Optimal BP in the setting of RAD is unknown. It
has been hypothesized that severe RAS might require higher BP to
maintain adequate blood flow across the stenosis; however, very low
rates of progressive renal failure in medically managed patients argue
against such a strategy.
Statins are associated with improved survival, slower lesion pro-
gression and reduced restenosis risk after renal stenting.223,224
Antiplatelet therapy should be part of BMT.
9.6.2 Revascularization
9.6.2.1 Impact on blood pressure control, renal function and survival
Uncontrolled trials have reported improved BP control in resistant
hypertensive patients following renal stenting,225,226 but previous227
and three recent major RCTs (Web Table 10) showed no difference
between endovascular therapy and BMT other than a minor reduc-
tion in antihypertensive medications after revascularization (2.96 vs.
3.18 drugs).228–231 Data do not support a benefit of stenting based
on the degree of stenosis, haemodynamic significance of the lesion or
higher pre-treatment BP.230
Regarding renal function, the Cardiovascular Outcomes in
Renal Atherosclerotic Lesions (CORAL) trial reported no benefit
from endovascular therapy over BMT.227 Progressive renal
failure occurred in 16.8% in the endovascular therapy group vs.
18.9% in the BMT group (P = 0.34) and permanent renal replacement
therapy occurred in 3.5% vs. 1.7%, respectively (P = 0.11).
Renal artery dissection was reported in 2.4% of the endovascular
therapy group. The two other RCTs showed similar findings even
in the highest risk groups, including severe kidney ischaemia
and impaired or rapidly decreasing kidney function. There was no
advantage for revascularization with regard to CV morbidity and
mortality.229,231,232
9.6.2.2 Revascularization in specific indications
With the low evidence of a potential benefit for revascularization
over medical therapy, renal revascularization could only be consid-
ered in patients with anatomically and functionally significant RAS
with the following particular aetiology or clinical scenarios.
9.6.2.2.1 Renal artery disease due to fibromuscular dysplasia. The preva-
lence of renal FMD is considered to be < 1% in the general popula-
tion233 and more common in women than men by a ratio of 9:1.
Renovascular hypertension is the most common clinical presentation
of FMD. Revascularization of FMD-related lesions should be recom-
mended only in cases of symptomatic FMD with signs of organ
ischaemia.206 Renal balloon angioplasty is the first-line revasculariza-
tion technique and stenting should be considered in the management
of dissection or balloon angioplasty failure.234–236 In a meta-analysis
(47 studies for endovascular therapy, 1616 patients; 23 studies for
open surgery, 1014 patients), major complication rates and mortality
rates were lower in the case of endovascular therapy (6.3% and 0.9%
vs. 15.4% and 1.2%, respectively).236 Therefore, open surgery should
be reserved for the management of stenosis associated with complex
aneurysms, complex lesions (arterial bifurcation or branches) or
endovascular therapy failure.206
9.6.2.2.2 Renal artery disease in flash pulmonary oedema or congestive
heart failure. Patients with sudden onset or ‘flash’ pulmonary
oedema or congestive heart failure predominantly with preserved
left ventricular function may be candidates for endovascular
therapy,208,237–239 although a subanalysis of the CORAL trial was not
conclusive.229
9.6.2.2.3. Renal artery disease and acute oligo-anuric renal failure. Patients
with acute oligo-anuric renal failure with kidney ischaemia may be
candidates for revascularization in some rare cases of bilateral RAS
without significant renal atrophy.
Recommendations for diagnostic strategies for renal
artery disease
Recommendations Classa Levelb
DUS (as first-line), CTAc and MRAd are rec-
ommended imaging modalities to establish a
diagnosis of RAD.204,212
I B
DSA may be considered to confirm a diag-
nosis of RAD when clinical suspicion is high
and the results of non-invasive examinations
are inconclusive.212,215
IIb C
Renal scintigraphy, plasma renin measure-
ments before and after ACEI provocation
and vein renin measurements are not rec-
ommended for screening of atherosclerotic
RAD.204
III C
ACEI = angiotensin-converting enzyme inhibitor; CTA = computed tomography
angiography; DSA = digital subtraction angiography; DUS = duplex ultrasound;
eGFR = estimated glomerular filtration rate; MRA = magnetic resonance angiog-
raphy; RAD = renal artery disease.
aClass of recommendation.
bLevel of evidence.
cWhen eGFR is >_ 60 mL/min.
dWhen eGFR is >_ 30 mL/min.
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9.6.2.3 Technical considerations for revascularization
See Web addenda 9.6.2.3.
10. Lower extremity artery
disease
Key messages
• Most patients with LEAD are asymptomatic. Walking capacity
must be assessed to detect clinically masked LEAD.
• The clinical signs vary broadly. Atypical symptoms are frequent.
• Even asymptomatic patients with LEAD are at high risk of CV
events and will benefit from most CV preventive strategies, espe-
cially strict control of risk factors.
• Antithrombotic therapies are indicated in patients with sympto-
matic LEAD. There is no proven benefit for their use in asympto-
matic patients.
• Ankle-brachial index is indicated as a first-line test for screening
and diagnosis of LEAD. DUS is the first imaging method.
• Data from anatomical imaging tests should always be analysed in
conjunction with symptoms and haemodynamic tests prior to
treatment decision.
• In patients with intermittent claudication, CV prevention and
exercise training are the cornerstones of management. If daily life
activity is severely compromised, revascularization can be pro-
posed, along with exercise therapy.
• Chronic limb-threatening ischaemia specifies clinical patterns with a
vulnerable limb viability related to several factors. The risk is strati-
fied according to the severity of ischaemia, wounds and infection.
• Early recognition of tissue loss and/or infection and referral to a
vascular specialist is mandatory for limb salvage by a multidiscipli-
nary approach. Revascularization is indicated whenever feasible.
• Acute limb ischaemia with neurological deficit mandates urgent
revascularization.
10.1. Clinical presentation and natural
history
LEAD has several different presentations, categorized according to
the Fontaine or Rutherford classifications (Table 6). Even with a simi-
lar extent and level of disease progression, symptoms and their inten-
sity may vary from one patient to another. The current background
information and detailed discussion of the data for the following sec-
tion of these Guidelines can be found in ESC CardioMed.
Most patients are asymptomatic, detected either by a low ABI
(<0.90) or pulse abolition. Among these, a subset may have severe dis-
ease without symptoms, which can be related to their incapacity to
walk enough to reveal symptoms (e.g. heart failure) and/or reduced
pain sensitivity (e.g. diabetic neuropathy). This subgroup should be quali-
fied as ‘masked LEAD’. In a study of 460 patients with LEAD, one-third
of asymptomatic patients were unable to walk more than six blocks,
corresponding to this concept.244 These patients were older, more
often women, with higher rates of neuropathy and multiple comorbid-
ities. While all asymptomatic patients are at increased risk of CV events,
the subgroup with masked LEAD is also at high risk of limb events. This
situation explains how a subset of patients presents a specific path with
‘asymptomatic’ disease shifting rapidly to severe LEAD. A typical presen-
tation is an elderly patient with several comorbidities who presents with
toe necrosis after a trivial wound (e.g. after aggressive nail clipping). It is
important to identify these patients to educate them about foot protec-
tion. Hence, prior to the estimation of pain when walking, a clinical
assessment of walking ability is necessary, and clinical examination
should also look for neuropathy. LEAD can also be clinically masked in
one leg when the other one has more disabling disease.
In symptomatic patients, the most typical presentation is IC. The
Edinburgh Claudication Questionnaire is a standardized method to
screen and diagnose typical IC.245
CLTI is defined by the presence of ischaemic rest pain, with or
without tissue loss (ulcers, gangrene) or infection. When present,
Recommendations for treatment strategies for renal
artery disease
Recommendations Classa Levelb
Medical therapy
ACEIs/ARBs are recommended for treat-
ment of hypertension associated with unilat-
eral RAS.219–222,240
I B
Calcium channel blockers, beta-blockers
and diuretics are recommended for treat-
ment of hypertension associated with renal
artery disease.
I C
ACEIs/ARBs may be considered in bilateral
severe RAS and in the case of stenosis in a
single functioning kidney, if well-tolerated
and under close monitoring.219,221
IIb B
Revascularization
Routine revascularization is not recom-
mended in RAS secondary to
atherosclerosis.229,231,232
III A
In cases of hypertension and/or signs of
renal impairment related to renal arterial
fibromuscular dysplasia, balloon angioplasty
with bailout stenting should be
considered.234–236
IIa B
Balloon angioplasty, with or without stent-
ing, may be considered in selected patients
with RAS and unexplained recurrent con-
gestive heart failure or sudden pulmonary
oedema.229,237,238
IIb C
In the case of an indication for revasculariza-
tion, surgical revascularization should be
considered for patients with complex anat-
omy of the renal arteries, after a failed
endovascular procedure or during open
aortic surgery.241–243
IIa B
ACEIs = angiotensin-converting enzyme inhibitor; ARBs = angiotensin-receptor
blockers; RAS = renal artery stenosis.
aClass of recommendation.
bLevel of evidence.
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arterial ulcers are usually painful and are often complicated by local
infection and inflammation. When pain is absent, peripheral neuropa-
thy should be considered. While CLTI is a clinical diagnosis, it is often
associated with an ankle pressure <50 mmHg or toe pressure
<30 mmHg.246 Investigation of the microcirculation [i.e. transcutane-
ous oxygen pressure (TcPO2)] is helpful in some cases of medial
calcinosis.
Regular clinical examination is important in elderly patients, espe-
cially diabetic patients.247 Early recognition of tissue loss and referral
to a vascular specialist is mandatory to improve limb salvage. Primary
major amputation rates in patients unsuitable for revascularization
are high (20–25%).248 CLTI is also a marker for generalized, severe
atherosclerosis, with a 3-fold increased risk of MI, stroke and vascular
death as compared to patients with IC.246,248
Clinical examination is fundamental but the diagnosis must be con-
firmed by objective tests. Pulse palpation should be systematic.
Abdominal and/or groin auscultation is poorly sensitive. In severe
cases, inspection may show foot pallor in a resting leg, with extended
recoloration time (>2 s) after finger pressure.
Regarding the natural history, in a recent meta-analysis,249 most
patients with IC present increased 5-year cumulative CV-related
morbidity of 13% vs. 5% in the reference population. Regarding the
limb risk, at 5 years, 21% progress to CLTI, of whom 4–27% have
amputations.246
10.2 Diagnostic tests
10.2.1 Ankle-brachial index
The ABI is the first diagnostic step after clinical examination (see
chapter 4). An ABI <_0.90 has 75% sensitivity and 86% specificity to
diagnose LEAD.250 Its sensitivity is poorer in patients with diabetes or
end-stage CKD because of medial calcification.251 Patients with bor-
derline ABI (0.90–1.00) need further diagnostic tests (Table 3 and
chapter 4). When clinically suspected, a normal ABI (>0.90) does
not definitely rule out the diagnosis of LEAD; further post-exercise
ABI and/or DUS are necessary. In case of a high ABI (>1.40) related
to medial calcification, alternative tests such as toe pressure, toe-
brachial index (TBI) or Doppler waveform analysis of ankle arteries
are useful. Along with DUS, ABI can be used during patient follow-
up. It is also a good tool for stratifying the CV risk (see chapter 4).6
10.2.2 Treadmill test
The treadmill test (usually using the Strandness protocol at a speed
of 3 km/h and 10% slope) is an excellent tool for objective functional
assessment and unmasking moderate stenosis, as well as for exercise
rehabilitation follow-up. It is also helpful when the ischaemic origin of
limb pain is uncertain. The test is stopped when the patient is unable
to walk further because of pain, defining maximal walking distance
(WD). A post-exercise ankle SBP decrease >30 mmHg or a post-
exercise ABI decrease >20% are diagnostic for LEAD.251
10.2.3 Imaging methods
10.2.3.1 Ultrasound
DUS provides extensive information on arterial anatomy and haemo-
dynamics. It must be combined with ABI measurement. It presents
85–90% sensitivity and >95% specificity to detect stenosis >50%.253
A normal DUS at rest should be completed by a post-exercise test
when iliac stenosis is suspected, because of lower sensitivity. DUS is
operator dependent and good training is mandatory. DUS does not
present as a roadmap the entire vasculature. Another imaging techni-
que is usually required when revascularization is considered. DUS is
also important to address vein quality for bypass substitutes. It is the
method of choice for routine follow-up after revascularization.
Table 6 Clinical stages of lower extremity artery disease
Recommendations for ankle-brachial index
measurement
Recommendations Classa Levelb
Measurement of the ABI is indicated as a
first-line non-invasive test for screening and
diagnosis of LEAD.250,251
I C
In the case of incompressible ankle arteries or
ABI >1.40, alternative methods such as the
toe-brachial index, Doppler waveform analysis
or pulse volume recording are indicated.252
I C
ABI = ankle-brachial index; LEAD = lower extremity artery disease.
aClass of recommendation.
bLevel of evidence.
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10.2.3.2 Computed tomography angiography
In a meta-analysis, the reported sensitivity and specificity of CTA to
detect aorto-iliac stenoses >50% were 96% and 98%, respectively,
with similar sensitivity (97%) and specificity (94%) for the femoro-
popliteal region.254 The main advantages are visualization of calcifica-
tions, clips, stents, bypasses and concomitant aneurysms. Beyond
general limitations (radiation, nephrotoxicity and allergies), pitfalls are
severe calcifications (impeding the appreciation of stenosis, mostly in
distal arteries).
10.2.3.3 Magnetic resonance angiography
The sensitivity and specificity of MRA are 95% for diagnosing seg-
mental stenosis and occlusion. However, MRA tends to overestimate
the degree of stenosis.255 It cannot visualize arterial calcifications, useful
for the estimation of stenosis severity in highly calcified lesions. This is a
limitation for selection of the anastomotic site of surgical bypass. The
visualization of steel stents is poor. In expert centres, MRA has a higher
diagnostic accuracy for tibial arteries than DUS and CTA.
10.2.3.4 Digital subtraction angiography
DSA is often required for guiding percutaneous peripheral interven-
tional procedures or for the identification of patent arteries for distal
bypass. It is also often needed for below-the-knee arteries, especially
in patients with CLTI, because of the limitation of all other imaging
tools to detect ankle/pedal segments suitable for distal bypass.
10.2.3.5 Cardiovascular screening in patients with LEAD
Patients with LEAD often have other concomitant arterial lesions,
including other PADs and AAA. See Web addenda 10.2.3.5 and
chapter 11.
10.2.4 Other tests
Toe systolic BP, TBI and TcPO2 are useful in patients with medial cal-
cinosis and incompressible arteries. For further details see Web
addenda 10.2.4.
10.3 Medical treatment
The therapeutic options addressed here are those to improve limb
symptoms or salvage. Treatments proposed to reduce other CV
events and mortality are addressed in chapter 4.
General prevention strategies can improve limb events. Smoking
cessation provides the most noticeable improvement in WD when
combined with regular exercise, especially when lesions are located
below the femoral arteries. In patients with IC, the natural history is
deteriorated by ongoing tobacco use, with increased risk of
amputation.25,260
Several studies have shown that statins significantly improve the
CV prognosis of patients with IC or CLTI.30,34 Additionally, several
meta-analyses have shown a relevant improvement in pain-free and
maximal WD with the use of statins.30,261 It is suggested that statins
could limit adverse limb events in patients with LEAD.33
In subjects with hypertension, calcium antagonists or ACEIs/ARBs
should be preferred because of their potential in peripheral arterial
dilatation. A meta-analysis262 showed improved maximal and pain-
free WD when using an ACEI over placebo; however, two of six
RCT reports have been recently withdrawn because of unreliable
data, and the meta-analysis of the remaining studies is inconclusive.263
The benefit of verapamil in improving WD in LEAD has been shown
in a randomized study.264 Because of comorbidities such as heart fail-
ure, beta-blockers are indicated in some patients with LEAD. Studies
have shown that beta-blockers, in particular nebivolol, are safe in
patients with IC without negative effects on WD.49 Metoprolol and
nebivolol have been compared in a double-blind RCT including 128
beta-blocker-naive patients with IC and hypertension.265 After a 48-
week treatment period, both drugs were well tolerated and
decreased BP equally. In both groups, maximal WD improved signifi-
cantly. Nebivolol showed an advantage, with significant improvement
in pain-free WD [þ34% (P < 0.003) vs. þ17% for metoprolol (P <
0.12)]. In a single-centre study of 1873 consecutive CLTI patients
who received endovascular therapy, those treated with other beta-
blockers did not have a poorer clinical outcome.266 In a multicentre
registry of 1273 patients hospitalized for severe LEAD (of whom
65% had CLTI and 28% were on beta-blocker therapy), death and
amputation rates did not differ among those with vs. without beta-
blocker.267
10.4 Revascularization options: general
aspects
See Web addenda 10.4.
10.5 Management of intermittent
claudication
10.5.1 Exercise therapy
In patients with IC, exercise therapy (ExT) is effective and improves
symptoms and QOL and increases maximal WD. In 30 RCTs includ-
ing 1816 patients with stable leg pain, ExT improved maximal WD on
a treadmill by almost 5 min compared with usual care.268 Pain-free
and maximal WD were increased on average by 82 and 109 m,
respectively. Improvement was observed up to 2 years. Moreover,
ExT improved QOL. Exercise did not improve ABI. Whether ExT
reduces CV events and improves life expectancy is still unclear.
Supervised ExT is more effective than unsupervised ExT.11,269
Recommendations on imaging in patients with lower
extremity artery disease
Recommendations Classa Levelb
DUS is indicated as a first-line imaging
method to confirm LEAD lesions.253
I C
DUS and/or CTA and/or MRA are indicated
for anatomical characterization of LEAD
lesions and guidance for optimal revasculari-
zation strategy.254–257
I C
Data from an anatomical imaging test should
always be analysed in conjunction with
symptoms and haemodynamic tests prior to
a treatment decision.246
I C
DUS screening for AAA should be
considered.258,259 IIa C
AAA = abdominal aorta aneurysm; CTA = computed tomography angiography;
DUS = duplex ultrasound; LEAD = lower extremity artery disease; MRA = mag-
netic resonance angiography.
aClass of recommendation.
bLevel of evidence.
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..In 14 trials with participants assigned to either supervised ExT or
unsupervised ExT (1002 participants), lasting from 6 weeks to
12 months, maximal and pain-free WD increased by almost 180 m in
favour of supervised ExT. These benefits remained at 1 year. Most
studies use programmes of at least 3 months, with a minimum of 3 h/
week, with walking to the maximal or submaximal distance. Long-
term benefits of ExT are less clear and largely depend on patient
compliance. Supervised ExT is safe and routine cardiac screening
beforehand is not required.270 It is also more cost effective than unsu-
pervised ExT,271 but it is not reimbursed or available everywhere.
Although home-based walking ExT is not as effective as supervised
ExT, it is a useful alternative, with positive effects on QOL and func-
tional walking capacity vs. walking advice alone.272,273 Alternative
exercise modes (e.g. cycling, strength training and upper-arm ergo-
metry) may be useful when walking exercise is not an option for
patients, as these have also been shown to be effective.274 ExT is
impossible in patients with CLTI but can be considered after success-
ful revascularization.275,276
10.5.2 Pharmacotherapy to decrease walking impairment
Some antihypertensive drugs (e.g. verapamil),264 statins,277,278 anti-
platelet agents and prostanoids (prostaglandins I2 and E1)279 have
some favourable effects on WD and leg functioning (see above).
Other pharmacological agents claim to increase WD in patients
with IC without other effects on CV health. The drugs mostly
studied are cilostazol, naftidrofuryl, pentoxifylline, buflomedil, car-
nitine and propionyl-L-carnitine.261,280 However, objective docu-
mentation of such an effect is limited. The beneficial effects on
WD, if any, are generally mild to moderate, with large variability.261
Also, the incremental benefit of these treatments in addition to
ExT and statins is unknown. For further details see Web addenda
10.5.2.
10.5.3 Revascularization for intermittent claudication
The anatomical location and extension of arterial lesions has an
impact on revascularization options.
10.5.3.1 Aorto-iliac lesions
Isolated aorto-iliac lesions are a common cause of claudication. In
the case of short stenosis/occlusion (<5 cm) of iliac arteries, endo-
vascular therapy gives good long-term patency (>_90% over
5 years) with a low risk of complications.281 In cases of ilio-femoral
lesions, a hybrid procedure is indicated, usually endarterectomy or
bypass at the femoral level combined with endovascular therapy of
iliac arteries, even with long occlusions. If the occlusion extends to
the infrarenal aorta, covered endovascular reconstruction of an
aortic bifurcation can be considered. In a small series, 1- and 2-year
primary patency was 87% and 82%, respectively.282 If the occlusion
comprises the aorta up to the renal arteries and iliac arteries,
aorto-bifemoral bypass surgery is indicated in fit patients with
severe life-limiting claudication.283 In these extensive lesions,
endovascular therapy may be an option, but it is not free of perio-
perative risk and long-term occlusion. In the absence of any other
alternative, extra-anatomic bypass (e.g. axillary to femoral bypass)
may be considered.
10.5.3.2 Femoro-popliteal lesions
Femoro-popliteal lesions are common in claudicants. If the circulation
to the profunda femoral artery is normal, there is a good possibility
that the claudication will be relieved with ExT and intervention is
mostly unnecessary. If revascularization is needed, endovascular ther-
apy is the first choice in stenosis/occlusions <25 cm. If the occlusion/
stenosis is > 25 cm, endovascular recanalization is still possible, but
better long-term patency is achieved with surgical bypass, especially
when using the great saphenous vein (GSV). No head-to-head trials
comparing endovascular therapy and surgery are yet available. In the
Zilver-PTX trial, the 5-year primary patency with conventional and
drug-eluting stents was 43% and 66%, respectively.76 The 5-year
patency after above-the-knee femoro-popliteal bypass is > 80% with
GSV and 67% with prosthetic conduits.284 The challenge of endovas-
cular therapy is the long-term patency and durability of stents in the
femoro-popliteal region, where the artery is very mobile. Several
new endovascular solutions, such as atherectomy devices, drug-
eluting balloons and new stent designs, have been shown to improve
long-term patency.
10.5.4 Management strategy for intermittent
claudication
Several studies have demonstrated the efficacy of endovascular ther-
apy and open surgery on symptom relief, WD and QOL in claudi-
cants. However, these interventions have limited durability and may
be associated with mortality and morbidity. Thus they should be
restricted to patients who do not respond favourably to ExT (e.g.
after a 3-month period of ExT) or when disabling symptoms substan-
tially alter daily life activities. A systematic review of 12 trials (1548
patients) comparing medical therapy, ExT, endovascular therapy and
open surgery in claudicants showed that, compared with the former,
each of the three other alternatives was associated with improved
WD, claudication symptoms and QOL.285 Compared with endovas-
cular therapy, open surgery may be associated with longer hospital
stays and higher complication rates but results in more durable
patency. The Claudication: Exercise Versus Endoluminal
Revascularization (CLEVER) trial randomized 111 patients with IC
and aorto-iliac lesions to BMT alone or in combination with super-
vised ExT or stenting.286 At 6 months, changes in maximal WD were
greatest with supervised ExT, while stenting provided greater
improvement in peak walking time than BMT alone. At 18 months
the difference in terms of peak walking time was not statistically dif-
ferent between supervised EXT and stenting.286 The management of
patients with intermittent claudication is summarized in Figure 5.
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Figure 5 Management of patients with intermittent claudicationa. CFA = common femoral artery; SFA = superficial femoral artery.
aRelated to atherosclerotic lower extremity artery disease (LEAD).
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Recommendations on revascularization of aorto-iliac occlusive lesionsc
Recommendations Classa Levelb
An endovascular-first strategy is recommended for short (i.e. <5 cm) occlusive lesions.291 I C
In patients fit for surgery, aorto-(bi)femoral bypass should be considered in aorto-iliac occlusions.281,292,293 IIa B
An endovascular-first strategy should be considered in long and/or bilateral lesions in patients with severe comorbidities.288,294,295 IIa B
An endovascular-first strategy may be considered for aorto-iliac occlusive lesions if done by an experienced team and if it does not compromise
subsequent surgical options.76,281–283,286
IIb B
Primary stent implantation rather than provisional stenting should be considered.294–296 IIa B
Open surgery should be considered in fit patients with an aortic occlusion extending up to the renal arteries. IIa C
In the case of ilio-femoral occlusive lesions, a hybrid procedure combining iliac stenting and femoral endarterectomy or bypass should
be considered.297–300
IIa C
Extra-anatomical bypass may be indicated for patients with no other alternatives for revascularization.301 IIb C
aClass of recommendation.
bLevel of evidence.
cThese recommendations apply for patients with intermittent claudication and severe chronic limb ischaemia.
Recommendations for the management of patients with intermittent claudication
Recommendations Classa Levelb
On top of general prevention, statins are indicated to improve walking distance.30,278 I A
In patients with intermittent claudication:
 supervised exercise training is recommended273,287–289 I A
 unsupervised exercise training is recommended when supervised exercise training is not feasible or available. I C
When daily life activities are compromised despite exercise therapy, revascularization should be considered. IIa C
When daily life activities are is severely compromised, revascularization should be considered in association with exercise therapy.288,290 IIa B
aClass of recommendation.
bLevel of evidence.
Recommendations on revascularization of femoro-popliteal occlusive lesionsc
Recommendations Classa Levelb
An endovascular-first strategy is recommended in short (i.e. <25 cm) lesions.302,303 I C
Primary stent implantation should be considered in short (i.e. <25 cm) lesions.304,305 IIa A
Drug-eluting balloons may be considered in short (i.e. <25 cm) lesions.77,306–310 IIb A
Drug-eluting stents may be considered for short (i.e. <25 cm) lesions.302,303,311 IIb B
Drug-eluting balloons may be considered for the treatment of in-stent restenosis.312,313 IIb B
In patients who are not at high risk for surgery, bypass surgery is indicated for long (i.e. >_25 cm) superficial femoral artery lesions when an
autologous vein is available and life expectancy is > 2 years.314
I B
The autologous saphenous vein is the conduit of choice for femoro-popliteal bypass.284,315 I A
When above-the-knee bypass is indicated, the use of a prosthetic conduit should be considered in the absence of any autologous saphenous
vein.284
IIa A
In patients unfit for surgery, endovascular therapy may be considered in long (i.e. >_25 cm) femoro-popliteal lesions.312 IIb C
aClass of recommendation.
bLevel of evidence.
cThese recommendations apply for patients with intermittent claudication and severe chronic limb ischaemia.
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..10.6 Chronic limb-threatening ischaemia
This entity includes clinical patterns with a threatened limb viability
related to several factors. In contrast to the former term ‘critical limb
ischaemia’, severe ischaemia is not the only underlying cause. Three
issues must be considered with the former terminology of critical
limb ischaemia. First, ‘critical’ implies that treatment is urgent to avoid
limb loss, while some patients can keep their legs for long periods of
time even in the absence of revascularization.316 Second, the increas-
ing predominance of diabetes in these situations, present in 50–70%
of cases, presents mostly as neuro-ischaemic diabetic foot ulcers.
Third, the risk of amputation not only depends on the severity of
ischaemia, but also the presence of a wound and infection. This
explains why ankle or toe pressures, measured to address LEAD
severity, are not a definition component of CLTI.
10.6.1 Chronic limb-threatening ischaemia severity and
risk stratification: the WIfI classification
A new classification system (WIfI) has been proposed as the initial
assessment of all patients with ischaemic rest pain or wounds.317 The
target population for this system includes any patient with
• ischaemic rest pain, typically in the forefoot with objectively con-
firmed haemodynamic studies (ABI <0.40, ankle pressure
<50 mmHg, toe pressure <30 mmHg, TcPO2 <30 mmHg),
• diabetic foot ulcer,
• non-healing lower limb or foot ulceration >_2 weeks duration or
• gangrene involving any portion of the foot or lower limb.
The three primary factors that constitute and contribute to the risk
of limb threat are wound (W), ischaemia (I) and foot infection (fI).
Each factor is graded into four categories (0 = none, 1 = mild, 2 =
moderate, 3 = severe). Table 7 shows the coding and clinical staging
according to the WIfI classification. Web Figure 2 provides an estima-
tion of the amputation risk according the WIfI classification. The man-
agement of patients with CLTI should consider the three
components of this classification system. Revascularization should
always be discussed, as its suitability is increased with more severe
stages (except stage 5).
10.6.2 Management of patients with chronic limb-
threatening ischaemia
The management of patients with CLTI is summarized in Figure 6. All
patients with CLTI must have BMT with correction of risk factors
(see section 9.3). In those with diabetes, glycaemic control is partic-
ularly important for improved limb-related outcomes, including
lower rates of major amputation and increased patency after infra-
popliteal revascularization.318,319 Proper wound care must be started
immediately, as well as the use of adapted footwear, treatment of
concomitant infection and pain control.
10.6.2.1 Revascularization
Revascularization should be attempted as much as possible.246,320–322
So far, only one randomized trial, the Bypass versus Angioplasty in
Severe Ischaemia of the Leg (BASIL) trial, has directly compared
endovascular therapy to open surgery in CLTI patients.323 At 2 years
there was no significant difference between endovascular therapy
and surgery regarding amputation-free survival. In survivors after
2 years, bypass surgery was associated with improved survival (on
average 7 months, P = 0.02) and amputation-free survival (6 months,
Table 7 Assessment of the risk of amputation: the WIFI classification (for further details see Mills et al317)
ABI = ankle-brachial index; TcPO2 = transcutaneous oxygen pressure.
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Figure 6 Management of patients with chronic limb-threatening ischaemia. EVT= endovascular therapy; GSV = great saphenous vein.
aIn bedridden, demented and/or frail patients, primary amputation should be considered.
bIn the absence of contra-indication for surgery and in the presence of adequate target for anastomosis/runoff.
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P = 0.06).314 These data are challenged by more recent endovascular
therapy techniques. So far, drug-eluting balloons in below-the-knee
disease have shown no superiority over plain balloon angioplasty.324
The results of two ongoing RCTs, BASIL-2 and Best Endovascular vs.
Best Surgical Therapy in Patients with Critical Limb Ischaemia (BEST-
CLI), are awaited.325,326 Meanwhile, in each anatomical region, both
revascularization options should be individually discussed.
10.6.2.1.1 Aorto-iliac disease. CLTI is almost never related to isolated
aorto-iliac disease, and downstream lesions are often concomitant. In
addition to CTA and/or MRA, complete DSA down to the plantar
arches is required for proper arterial network assessment and proce-
dure planning.327 Hybrid procedures (e.g. aorto-iliac stenting and dis-
tal bypass) should be encouraged in a one-step modality when
necessary.
10.6.2.1.2 Femoro-popliteal disease. CLTI is unlikely to be related to iso-
lated SFA lesions; usually femoro-popliteal involvement combined
with aorto-iliac or below-the-knee disease is found. In up to 40% of
cases, inflow treatment is needed.324 The revascularization strategy
should be judged on lesion complexity. If endovascular therapy is
chosen first, landing zones for potential bypass grafts should be pre-
served. When bypass surgery is decided, the bypass should be as
short as possible, using the saphenous vein.
10.6.2.1.3 Infra-popliteal disease. Extended infra-popliteal artery disease
is mainly seen in diabetic patients, often associated with SFA lesions
(inflow disease). Full-leg DSA down to the plantar arches is manda-
tory to explore all revascularization options.327 In stenotic lesions
and short occlusions, endovascular therapy can be the first choice. In
long occlusions of crural arteries, bypass with an autologous vein
gives superior long-term patency and leg survival. If the patient has
increased risk for surgery or does not have an autologous vein, endo-
vascular therapy can be attempted. The decision of revascularization
should also consider the angiosome concept, targeting the ischaemic
tissues. For further details, see Web addenda 10.6.2.1.3.1.
10.6.3 Spinal cord stimulation
See Web addenda 10.6.3.
10.6.4 Stem cell and gene therapy
Angiogenic gene and stem cell therapy are still being investigated,
with insufficient evidence in favour of these treatments.328–330 For
further details see Web addenda 10.6.4.
10.6.5 Amputation
10.6.5.1 Minor amputation
In case of CLTI, minor amputation (up to the forefoot level) is often
necessary to remove necrotic tissues with minor consequences on
patient’s mobility. Revascularization is needed before amputation to
improve wound healing. Foot TcPO2 and toe pressure can be useful
to delineate the amputation zone (see section 10.2.4).
10.6.5.2 Major amputation
Patients with extensive necrosis or infectious gangrene and those
who are non-ambulatory with severe comorbidities may be best
served with primary major amputation. This remains the last option
to avoid or halt general complications of irreversible limb ischaemia,
allowing in some cases patient recovery with rehabilitation and pros-
thesis. For a moribund patient, adequate analgesia and other suppor-
tive measures may also be an option.
Secondary amputation should be performed when revasculariza-
tion has failed and re-intervention is no longer possible or when the
limb continues to deteriorate because of infection or necrosis despite
patent graft and optimal management. In any case, infragenicular
amputation should be preferred, because the knee joint allows better
mobility with a prosthesis. For bedridden patients, femoral amputa-
tion may be the best option.
Recommendations on revascularization of infra-popli-
teal occlusive lesions
Recommendations Classa Levelb
In the case of CLTI, infra-popliteal revascula-
rization is indicated for limb salvage.320–326
I C
For revascularization of infra-popliteal arteries:
 bypass using the great saphenous vein is
indicated
I A
 endovascular therapy should be
considered.320–326
IIa B
CLTI = chronic limb threatening ischaemia.
aClass of recommendation.
bLevel of evidence.
Recommendations on the management of chronic
limb-threatening ischaemia
Recommendations Classa Levelb
Early recognition of tissue loss and/or infec-
tion and referral to the vascular team is
mandatory to improve limb salvage.317
I C
In patients with CLTI, assessment of the risk
of amputation is indicated.317
I C
In patients with CLTI and diabetes, optimal
glycaemic control is recommended.318,319
I C
For limb salvage, revascularization is indi-
cated whenever feasible.314
I B
In CLTI patients with below-the-knee
lesions, angiography including foot runoff
should be considered prior to
revascularization.
IIa C
In patients with CLTI, stem cell/gene ther-
apy is not indicated.328
III B
CLTI = chronic limb threatening ischaemia.
aClass of recommendation.
bLevel of evidence.
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10.7 Acute limb ischaemia
Acute limb ischaemia is caused by an abrupt decrease in arterial per-
fusion of the limb. Potential causes are artery disease progression,
cardiac embolization, aortic dissection or embolization, graft throm-
bosis, thrombosis of a popliteal aneurysm or cyst, popliteal artery
entrapment syndrome, trauma, phlegmasia cerulea dolens, ergotism,
hypercoagulable states and iatrogenic complications related to vascu-
lar procedures. Limb viability is threatened and prompt management
is needed for limb salvage.
Once the clinical diagnosis is established, treatment with unfractio-
nated heparin should be given, along with appropriate analgesia.246,331
The emergency level and the choice of therapeutic strategy depend
on the clinical presentation, mainly the presence of neurological defi-
cits. The clinical categories are presented in Table 8.
In the case of neurological deficit, urgent revascularization is man-
datory; imaging should not delay intervention. The imaging method
depends on its immediate availability. DUS and DSA are mostly used
in these situations.
Different revascularization modalities can be applied, including per-
cutaneous catheter–directed thrombolytic therapy, percutaneous
mechanical thrombus extraction or thrombo-aspiration (with or
without thrombolytic therapy) and surgical thrombectomy, bypass
and/or arterial repair. The strategy will depend on the presence of a
neurological deficit, ischaemia duration, its localization, comorbidities,
type of conduit (artery or graft) and therapy-related risks and out-
comes. Owing to reduced morbidity and mortality, endovascular
therapy is often preferred, especially in patients with severe comor-
bidities. Thrombus extraction, thrombo-aspiration and surgical
thrombectomy are indicated in the case of neurological deficit, while
catheter-directed thrombolytic therapy is more appropriate in less
severe cases without neurological deficit. The modern concept of the
combination of intra-arterial thrombolysis and catheter-based clot
removal is associated with 6-month amputation rates of < 10%.246
Systemic thrombolysis has no role in the treatment of patients with
acute limb ischaemia.
Based on RCTs, there is no clear superiority of local thrombolysis
vs. open surgery on 30-day mortality or limb salvage.333 After throm-
bus removal, the pre-existing arterial lesion should be treated by
endovascular therapy or open surgery. Lower extremity four-
compartment fasciotomies should be performed in patients with
long-lasting ischaemia to prevent a post-reperfusion compartment
syndrome. The management of acute limb ischaemia is summarized
in Figure 7.
Table 8 Clinical categories of acute limb ischaemia332 Recommendations for the management of patients pre-
senting with acute limb ischaemia
Recommendations Classa Levelb
In the case of neurological deficit, urgent
revascularization is indicated.246,331,c
I C
In the absence of neurological deficit, revas-
cularization is indicated within hours after
initial imaging in a case-by-case
decision.246,331
I C
Heparin and analgesics are indicated as soon
as possible.246,331
I C
aClass of recommendation.
bLevel of evidence.
cIn this case, imaging should not delay intervention.
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..10.8 Blue toe syndrome
Another particular clinical presentation is blue toe syndrome. This is
characterized by a sudden cyanotic discoloration of one or more
toes. It is usually due to embolic atherosclerotic debris from the
proximal arteries. For further details see Web addenda 10.8.
11. Multisite artery disease
Key messages
• Multisite artery disease (MSAD) is common in patients with athe-
rosclerotic involvement in one vascular bed, ranging from 10 to
15% in patients with CAD to 60 to 70% in patients with severe
carotid stenosis or LEAD.
• MSAD is invariably associated with worse clinical outcomes;
however, screening for asymptomatic disease in additional vascu-
lar sites has not been proven to improve prognosis.
• In patients with any presentation of PADs, clinical assessment of
symptoms and physical signs of other localizations and/or CAD is
necessary, and in case of clinical suspicion, further tests may be
planned.
• Systematic screening for asymptomatic MSAD is not indicated
for any presentation of PADs, as it would not consistently lead
to a modification of management strategy. It may be interesting
in some cases for risk stratification (e.g. an antiplatelet therapy
strategy beyond 1 year in patients who benefited from coronary
stenting for ACS).
• In some situations the identification of asymptomatic lesions may
affect patient management. This is the case for patients under-
going CABG, where ABI measurement may be considered,
Figure 7 Management of acute limb ischaemia. CTA = computed tomography angiography; DSA = digital subtraction ultrasound; DUS = duplex
ultrasound.
aImaging should not delay revascularization.
bSpecific etiological work-up is necessary (cardiac, aorta).
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especially when saphenous vein harvesting is planned, and carotid
screening should be considered in a subset of patients at high
risk of CAD.
• In patients scheduled for CABG with severe carotid stenoses,
prophylactic carotid revascularization should be considered in
recently symptomatic cases and may be considered in asympto-
matic cases after multidisciplinary discussion.
• In patients planned for carotid artery revascularization for asymp-
tomatic stenosis, preoperative coronary angiography for detec-
tion (and revascularization) of CAD may be considered.
Multisite artery disease (MSAD) is defined by the simultaneous
presence of clinically relevant atherosclerotic lesions in at least two
major vascular territories. Subclinical plaques are beyond the scope
of this document. While patients with MSAD are regularly encoun-
tered in clinical practice, robust data on the management of these
patients are scarce. For the management of these patients, clinical sta-
tus and comorbidities should be considered, in addition to the lesion
sites. Generally the treatment strategy should be decided case by
case within a multidisciplinary team and should focus first on the
symptomatic vascular site. The current background information and
detailed discussion of the data for the following section of these
Guidelines can be found in ESC CardioMed.
11.1 Multisite artery disease:
epidemiology and impact prognosis
Among 3.6 million American volunteers for a systematic ultrasound
screening for LEAD, CAD and AAA, the proportion of subjects with
two or more localizations increased with age, from 0.04% at
40–50 years to 3.6% at 81–90 years.334 Figure 8 summarizes the prev-
alence of MSAD when atherosclerotic disease is diagnosed in one
territory.
Although several studies have demonstrated that patients with
MSAD have a significantly worse clinical outcome as compared
with patients with single vascular site disease, the only RCT
designed to assess the impact on prognosis of systematic screening
for MSAD in patients with high-risk CAD (three-vessel CAD and/
or with an ACS at age >75 years) failed to prove any significant
benefit.344 The Aggressive detection and Management of the
Extension of atherothrombosis in high Risk coronary patients In
comparison with standard of Care for coronary Atherosclerosis
(AMERICA) trial randomized 521 patients to a proactive strategy
(total-body DUS and ABI measurement associated with intensive
medical therapy) or to conventional strategy (no screening for
asymptomatic MSAD and standard medical therapy); at the 2-year
follow-up, the primary composite endpoint, including death, any
ischaemic event leading to rehospitalization or any evidence of
organ failure, occurred in 47.4% and 46.9% of patients, respectively
(P > 0.2).344 Hence the clinical benefit of systematic screening for
asymptomatic MSAD in patients with known atherosclerotic dis-
ease appears questionable.
11.2 Screening for and management of
multisite artery disease
11.2.1 Peripheral arterial diseases in patients presenting
with coronary artery disease
11.2.1.1 Carotid artery disease in patients scheduled for coronary artery
bypass grafting
Web Table 11 details the epidemiology of CAD and the incidence of
stroke among patients undergoing isolated CABG (without synchro-
nous/staged CEA).341 In another study, unilateral 50–99% carotid
stenosis was found in 11% of patients, bilateral 50–99% stenosis in
5.6% and unilateral occlusion in 1.3%.345
Figure 8 Reported rate ranges of other localizations of atherosclerosis in patients with a specific arterial disease.51, 335–343 The graph reports the
rates of concomitant arterial diseases in patients presenting an arterial disease in one territory (e.g. in patients with CAD, 5 - 9% of cases have con-
comitant carotid stenosis >70%). ABI = ankle-brachial index; CAD = coronary artery disease; LEAD = lower extremity artery disease; RAS = renal
artery stenosis.
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Ischaemic stroke after CABG is multifactorial, including aortic
embolism during manipulation, cannulation/decannulation and graft
anastomosis to the ascending aorta; platelet aggregation during cardi-
opulmonary bypass (CPB) and hypercoagulable states; carotid embo-
lization; postoperative AF and haemodynamic instability, especially in
patients with impaired cerebral vascular reserve.346
The impact of asymptomatic carotid stenosis on stroke risk after
CABG is modest, except for bilateral stenoses or unilateral occlusion.
In a systematic review, 86% of postoperative strokes were not attrib-
uted to carotid disease. Carotid stenosis appears as a marker of
severe aortic atherosclerosis and stroke risk rather than the direct
cause. Conversely, a history of prior stroke/TIA is a significant risk
factor for post-CABG stroke.341,347–349 Evidence of the benefits of
prophylactic revascularization of asymptomatic carotid stenoses in all
CABG candidates to reduce perioperative stroke is lacking. The deci-
sion to perform CEA/CAS in these patients should be made by a mul-
tidisciplinary team. It may be reasonable to restrict prophylactic
carotid revascularization to patients at highest risk of postoperative
stroke, i.e. patients with severe bilateral lesions or a history of prior
stroke/TIA.341,348–350
The timing and the modality of carotid revascularization (CEA or
CAS) are controversial and should be individualized based on clinical
presentation, level of emergency and severity of carotid and coronary
artery diseases. Web Table 12 details the results of meta-analyses
evaluating outcomes following different scenarios. No specific strat-
egy is clearly safer. A recent RCT did not report lower stroke rate
for off-pump vs. on-pump surgery.351
The two-staged CEA strategies provide higher risk of periproce-
dural MI if the carotid artery is revascularized first and a trend
towards increased cerebral risk if CABG is performed first. In a
recent RCT in patients with unilateral asymptomatic carotid stenosis,
CABG followed by CEA was the worst strategy, with a higher 90-day
stroke and death rate compared with CABG with previous or syn-
chronous CEA (8.8% vs. 1.0%; P = 0.02).352
The higher risk of cerebral embolization from aortic arch pla-
ques may explain why CAS is not associated with lower proce-
dural risks. If CAS is performed before elective CABG, the need
for DAPT usually delays cardiac surgery for at least 4 weeks,
exposing the patient to the risk of MI between the staged CAS and
CABG (0–1.9%).353,354 Some authors performed CAS immedi-
ately prior to CABG and reported low death/stroke rates.355
Among 132 patients with same-day CAS plus cardiac surgery, the
in-hospital stroke rate was 0.75%, while 5- and 10-year freedom
from neurological events was 95% and 85%, respectively.356 In a
single-centre propensity-matched analysis of 350 patients under-
going carotid revascularization within 90 days before cardiac sur-
gery, staged CAS plus cardiac surgery and combined CEA plus
cardiac surgery had similar early outcomes (death/stroke/MI),
whereas staged CEA plus cardiac surgery incurred the highest
risk, driven by interstage MI. Beyond 1 year, patients with either
staged or combined CEA plus cardiac surgery had a 3-fold higher
rate of MACE compared with patients undergoing staged CAS
plus cardiac surgery.357 However, staged CAS plus cardiac surgery
entails an increased bleeding risk during CABG (if performed
within the DAPT period).
Two studies suggest that limiting DUS to patients with at least one
risk factor (age >70 years, history of cerebrovascular disease, pres-
ence of a carotid bruit, multivessel CAD or LEAD) identifies all
patients with carotid stenosis >70%, reducing the total number of
scans by 40%.338,358 However, a study comparing patients undergoing
a preoperative carotid scan before cardiac surgery with those with-
out screening reported no difference in perioperative mortality and
stroke.345 But only 12% of those with severe carotid stenosis under-
went synchronous CABG plus CEA. Hence routine carotid DUS
identifies only the minority of patients who will develop perioperative
stoke, without clearly evidenced benefit of prophylactic carotid
revascularization. Carotid DUS is indicated in patients with recent
(<6 months) stroke/TIA. No carotid imaging is indicated when
CABG is urgent, unless neurological symptoms occurred in the pre-
vious 6 months.
Recommendations on screening for carotid disease in
patients undergoing coronary artery bypass grafting
Recommendations Classa Levelb
In patients undergoing CABG, DUS is rec-
ommended in patients with a recent
(<6 months) history of TIA/stroke.345,358
I B
In patients with no recent (<6 months) his-
tory of TIA/stroke, DUS may be considered
in the following cases: age >_70 years, multi-
vessel coronary artery disease, concomitant
LEAD or carotid bruit.345,358
IIb B
Screening for carotid stenosis is not indi-
cated in patients requiring urgent CABG
with no recent stroke/TIA.
III C
CABG = coronary artery bypass grafting; DUS = duplex ultrasound; LEAD =
lower extremity artery disease; TIA = transient ischaemic attack.
aClass of recommendation.
bLevel of evidence.
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11.2.1.2 Carotid artery stenosis in other coronary artery disease patients
(without coronary artery bypass grafting)
The available data regarding the prevalence of carotid stenosis in
these patients and the lack of evidence of any effect on outcome lead
to the conclusion that carotid screening is not indicated in patients
with CAD other than in candidates for CABG. For further details
refer to Web addenda 11.2.1.2.
11.2.1.3. Renal artery disease in patients presenting with coronary artery
disease
In the absence of any proof of benefit, systematic screening for RAS
in patients with CAD cannot be recommended. For further details
refer to Web addenda 11.2.1.3. As in other patients, the indications
for imaging renal arteries are presented in Table 5.
11.2.1.4 Lower extremity artery disease in patients with coronary artery
disease
LEAD often coexists with CAD (Figure 8). It is often asymptomatic or
masked by limiting angina and/or dyspnoea. LEAD (ABI < 0.90) is
present in 13–16% of patients who have CAD at coronary angiogra-
phy.361,362 Left main coronary artery stenosis and multivessel CAD
were independent predictors. Patients with LEAD exhibit more
extensive, calcified and progressive coronary atherosclerosis.363
The coexistence of LEAD in CAD patients has been consistently
associated with worse outcome, although it is unclear whether LEAD
is a marker or a cause of cardiac adverse events.364,365 In the 3-year
follow-up of the PEGASUS trial, patients with concomitant LEAD had
adjusted 2-fold increased rates of all-cause death, CV death, stroke and
MACE.81 In ACS registries, in-hospital mortality, acute heart failure and
recurrent ischaemia rates were significantly higher (up to 5-fold) in sub-
jects with LEAD.340,343 In a pooled analysis of 19 867 patients enrolled
in RCTs on PCI, 8% had clinical LEAD, identified as an independent
predictor of mortality at 30 days (HR 1.67), 6 months (HR 1.76) and
1 year (HR 1.46).366 Concomitant LEAD (clinical or subclinical) is also
associated with worse outcome in patients undergoing CABG.367,368
In patients with CAD who have concomitant LEAD, strict risk fac-
tor control is mandatory, although no specific recommendations
exist, as compared with CAD patients without MSAD. In a post hoc
analysis of the CHARISMA trial, DAPT with aspirin and clopidogrel
was associated with a significant decrease in non-fatal MI compared
with aspirin alone,65 at a cost of increased minor bleeding. The poten-
tial benefits of DAPT in these patients need further confirmation.
In LEAD patients requiring coronary revascularization, the treat-
ment of CAD is usually prioritized, except in the case of CLTI.
Whether PCI or CABG should be favoured to treat CAD in patients
with LEAD is controversial.369,370 In the case of PCI, radial artery
access should be favoured. If the femoral approach is necessary, pre-
interventional assessment of the iliac and common femoral arteries
should be performed to minimize the risk of ischaemia/embolization
and to identify the best location for arterial puncture, since access
site complications are more frequent in these patients, particularly
when closure devices are used.371 In patients undergoing CABG with
advanced LEAD, the GSV should be spared whenever possible; later
success of peripheral arterial revascularization is strongly dependent
on the availability of sufficient autologous venous segments.372 Also,
saphenous vein harvesting may be associated with wound healing
delays in severe LEAD. This justifies the screening for LEAD prior to
use of the saphenous vein as bypass material, at least by clinical
examination and/or ABI. CPB during CABG causes a mean arterial
pressure drop and loss of pulsatile flow, entailing the risk of worsen-
ing CLTI. When off-pump CABG is not feasible, maintaining an
adequate mean arterial pressure and monitoring peripheral oxygen
Recommendations on the management of carotid
stenosis in patients undergoing coronary artery bypass
grafting
Recommendations Classa Levelb
It is recommended that the indication (and,
if so, the method and timing) for carotid
revascularization be individualized after dis-
cussion within a multidisciplinary team,
including a neurologist.
I C
In patients with a recent (<6 months) history of TIA/stroke who
are scheduled for CABG:
 Carotid revascularization should be con-
sidered in patients with 50–99% carotid
stenosis.359,360
 Carotid revascularization with CEA
should be considered as the first choice
in patients with 50–99% carotid
stenosis.359,360
IIa B
 Carotid revascularization is not recom-
mended in patients with carotid stenosis
<50%.
III C
In neurologically asymptomatic patients scheduled
for CABG:
 Routine prophylactic carotid revascula-
rization in patients with a 70–99% caro-
tid stenosis is not recommended.350
III B
 Carotid revascularization may be con-
sidered in patients with bilateral
70–99% carotid stenoses or 70–99%
carotid stenosis þ contralateral
occlusion.350
IIb B
 Carotid revascularization may be con-
sidered in patients with a 70–99% car-
otid stenosis in the presence of one or
more characteristics that may be asso-
ciated with an increased risk of ipsilat-
eral strokec in order to reduce stroke
risk beyond the perioperative period.
IIb C
CABG = coronary artery bypass grafting; CAS = carotid artery stenting; CEA =
carotid endarterectomy.
aClass of recommendation.
bLevel of evidence.
cSee Table 4.
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saturation in CLTI patients are strongly advisable during CPB.
Postoperatively, active clinical surveillance is needed to diagnose in a
timely fashion the compartment syndrome potentially caused by
ischaemia–reperfusion injury during CPB. The coexistence of LEAD,
even asymptomatic, may upset cardiac rehabilitation.373
Screening for LEAD by means of ABI could represent a non-
invasive and inexpensive method for prognostic stratification of
patients. However, the AMERICA trial failed to demonstrate the ben-
efit of a proactive strategy of MSAD screening in patients.344
However, the trial was small, with some limitations. It does not
exclude a role for screening for asymptomatic LEAD in CAD patients
for prognostic stratification. Importantly, in patients with severe
CAD, the presence of symptomatic or asymptomatic LEAD is associ-
ated with a high probability (almost 20%) of carotid stenosis.374
11.2.2. Coronary artery disease in patients presenting
with peripheral arterial diseases
11.2.2.1. Coronary artery disease in patients with carotid artery stenosis
In a study including 276 patients with non-cardioembolic ischaemic
stroke/TIA, coronary CTA detected coronary stenosis (>50%) in
18% of cases. The prevalence was 4-fold higher in the case of carotid
stenosis >50%.380 In a prospective investigation of 390 patients
undergoing elective CAS, systematic coronary angiography found
coronary artery stenosis >_70% in 61% of cases.381
In the case of severe carotid artery stenosis, the presence of associated
CAD requires prioritization of revascularization according to the patient’s
clinical status and to the severity of carotid and coronary disease. Carotid
revascularization should be performed first only in the case of unstable
neurological symptoms; asymptomatic carotid stenosis should be treated,
whenever appropriate, following CAD revascularization.
In an RCT, 426 patients planned for CEA and without a history of
CAD and normal electrocardiogram (ECG) and cardiac ultrasound
were randomized to either systematic coronary angiography (with
subsequent revascularization) or no coronary angiography.382
Significant CAD was found (and treated) before CEA in 39% of those
randomized to angiography, with no postoperative MI, vs. 2.9% in the
no-angiography group (P = 0.01). Importantly, PCI delayed CEA by a
median of 4 days (range 1–8 days), without neurological events and
without bleeding complications in patients on DAPT. At 6 years,
patients allocated to systematic coronary angiography had a lower
rate of MI (1.4% vs. 15.7%; P < 0.01) and improved survival (95% vs.
90%; P < 0.01).383 Hence routine preoperative coronary angiography
may be considered in patients undergoing elective CEA.
11.2.2.2 Coronary artery disease in patients undergoing vascular surgery
of lower limbs
In patients undergoing surgery for LEAD, the probability of significant
concomitant CAD at coronary angiography is 50–60%.384–386 For
the management of these patients, aortic and major vascular surgery
are classified as ‘high risk’ for cardiac complications, with an expected
30-day MACE rate (cardiac death and MI) >5%.387 The management
of CAD in patients requiring vascular surgery should be based on the
2014 ESC/ESA Guidelines on non-cardiac surgery.387
11.2.2.3 Coronary artery disease in patients with lower extremity artery
disease not undergoing vascular surgery
At least one-third of patients with LEAD have a history and/or
ECG signs of CAD, while two-thirds have an abnormal stress test
and up to 70% present at least single-vessel disease at coronary
angiography.69,388 The prevalence of CAD is 2- to 4-fold higher in
patients with LEAD vs. those without. In the Coronary CT
Angiography Evaluation For Clinical Outcomes: An International
Multicenter (CONFIRM) registry, among 7590 patients with
LEAD without a history and symptoms of heart disease, the preva-
lence of obstructive CAD at coronary CTA was 25%.389 In the
REACH registry, 57% of the participants with LEAD also suffered
from CAD.390 The severity of LEAD is related to the prevalence
of associated CAD; up to 90% of patients presenting with CLTI
also have CAD.
There is no evidence that the presence of CAD directly influences
limb outcomes in LEAD patients; however, in the CONFIRM registry,
obstructive CAD was associated with an annual mortality rate of
1.6% vs. 0.7% in the absence of severe CAD.389
Recommendation on screening for coronary artery dis-
ease in patients with carotid disease
Classa Levelb
In patients undergoing elective CEA, preop-
erative CAD screening, including coronary
angiography, may be considered.382,383
IIb B
CAD = coronary artery disease; CEA = carotid endarterectomy.
aClass of recommendation.
bLevel of evidence.
Recommendations for screening and management of
concomitant lower extremity artery disease and coro-
nary artery disease
Classa Levelb
In patients with LEAD, radial artery access is
recommended as the first option for coro-
nary angiography/intervention.365
I C
In patients with LEAD undergoing CABG,
sparing the autologous great saphenous vein
for potential future use for surgical periph-
eral revascularization should be considered.
IIa C
In patients undergoing CABG and requiring
saphenous vein harvesting, screening for
LEAD should be considered.
IIa C
In patients with CAD, screening for LEAD
by ABI measurement may be considered for
risk stratification.340,343,344,366–368,375–379
IIb B
ABI = ankle-brachial index; CABG = coronary artery bypass grafting; CAD = cor-
onary artery disease; LEAD = lower extremity artery disease; TIA = transient
ischaemic attack.
aClass of recommendation.
bLevel of evidence.
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The presence of CAD in patients with LEAD may require coronary
revascularization, depending on the severity and urgency of LEAD
symptoms. Risk factor modification and medical treatment recom-
mended for CAD also apply to LEAD.391 Screening for CAD in LEAD
patients may be useful for risk stratification, as morbidity and mortality
are mainly cardiac. Non-invasive screening can be performed by stress
testing or coronary CTA, but there is no evidence of improved out-
comes in LEAD patients with systematic screening for CAD.
11.2.3 Other peripheral localizations in patients with
peripheral arterial diseases
11.2.3.1 Carotid artery stenosis in patients with lower extremity artery
disease
Carotid stenosis is frequent in patients with LEAD (Figure 8), but
there is no evidence that the presence of CAS would influence lower
limb outcomes. The presence of CAD is a marker of worse CV prog-
nosis.392 For more details see Web addenda 11.2.3.1.
11.2.3.2 Renal artery disease in patients with lower extremity artery disease
While RAS is frequently discovered incidentally during imaging for
LEAD, it requires specific intervention. Opinions on whether athero-
sclerotic RAD could be a marker of worse CV prognosis in LEAD
patients are conflicting.335,393 The only report looking also at limb
outcome found no prognostic alteration in the case of concomitant
RAS.335 Systematic screening for RAS in patients with LEAD cannot
be recommended, as the therapeutic value of renal artery stenting is
questionable (see chapter 9).
For more details see Web addenda 11.2.3.2.
12. Cardiac conditions in
peripheral arterial diseases
Key messages
• Cardiac conditions other than CAD are frequent in patients with
PADs. This is especially the case for heart failure and atrial fibrilla-
tion in patients with LEAD.
• In patients with symptomatic PADs, screening for heart failure
should be considered.
• In patients with heart failure, screening for LEAD may be consid-
ered. Full vascular assessment is indicated in patients planned for
heart transplantation or a cardiac assist device.
• In patients with stable PADs who have AF, anticoagulation is the
priority and suffices in most cases. In the case of recent endovas-
cular revascularization, a period of combination therapy (anticoa-
gulant þ antiplatelet therapies) should be considered according
to the bleeding and thrombotic risks. The period of combination
therapy should be as brief as possible.
• In patients undergoing transcatheter aortic valve implantation or
other structural interventions, screening for LEAD and UEAD is
indicated.
12.1 Introduction
Cardiac diseases are frequent in patients with PADs. The simulta-
neous presence of PADs and CAD is addressed in chapter 11.
Here we address the most important issues related to PADs
patients with coexisting heart failure, AF and valvular heart disease
(VHD). Such coexistence may carry important prognostic and
Table 9 Indication for screening of associated atherosclerotic disease in additional vascular territories
CABG = coronary artery bypass grafting; CAD = coronary artery disease; CAS: carotid artery stenting; CEA = coronary endarterectomy; CKD = chronic kidney disease; ECG
= electrocardiogram; LEAD = lower extremity artery disease; NR = no recommendation (not enough evidence to support systematic screening); TIA = transient ischaemic
attack; U = uncertain.
aEspecially when venous harvesting is planned for bypass.
bIn patients with symptomatic cerebrovascular disease.
cIn patients with asymptomatic carotid disease and: age >_ 70 years, multivessel CAD, associated LEAD or carotid bruit.
dScreening with ECG is recommended in all patients and with imaging stress testing in patients with poor functional capacity and more than two of the following: history of
CAD, heart failure, stroke or TIA, CKD, diabetes mellitus requiring insulin therapy.
804 ESC Guidelines
D
ow
nloaded from
 https://academ
ic.oup.com
/eurheartj/article-abstract/39/9/763/4095038 by Theology Library, U
niversity of H
elsinki user on 10 M
ay 2019
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
.
therapeutic implications and often needs a multidisciplinary
approach. The current background information and detailed dis-
cussion of the data for the following section of these Guidelines
can be found in ESC CardioMed.
12.2 Heart failure and peripheral arterial
diseases
There are multiple pathways linking LEAD and heart failure (Web
Figure 3). Together with diabetes, smoking and other risk factors,
inflammation may be one of the common factors leading to the devel-
opment of heart failure in PADs patients.394 Data on the coexistence
of the two conditions are generally limited to subjects with heart fail-
ure and LEAD.
LEAD is associated with increased risk for incident heart failure. It is
often associated with overt atherosclerosis involving CAD, which may
cause subsequent heart failure.53 Also, elevated aortic stiffness
increases left ventricular (LV) afterload and high pulse pressure impairs
coronary blood flow, resulting in hypertension, LV hypertrophy, dia-
stolic dysfunction and ultimately heart failure.395,396 Importantly, skele-
tal muscle involvement and deconditioning in LEAD may affect heart
failure severity.397,398 On the other hand, functional limitation due to
heart failure is likely to mask symptoms of LEAD, causing underestima-
tion of the number of patients with both conditions.
12.2.1 Epidemiology
Overall, LV dysfunction and heart failure are more frequent in
patients with PADs. The evidence is mostly presented in patients
with LEAD. See Web addenda 12.2.1.
12.2.2. Heart failure in patients with peripheral arterial
diseases
Despite the high prevalence and incidence of heart failure in patients
with PADs, outcome data for this group are very limited. It is most likely,
however, that this combination is associated with increased CV morbid-
ity and mortality. Evaluation of LV function in PADs may be of value for
better risk stratification for future CV events and comprehensive man-
agement of patients’ CV diseases.399 This is particularly important when
an intermediate- or high-risk vascular intervention is planned.387 The pri-
mary assessment should include medical history, physical examination
and resting ECG. In case of any abnormalities suggestive of heart failure,
transthoracic echocardiography (TTE) or measurement of natriuretic
peptides should be undertaken.400 Natriuretic peptides are particularly
useful in patients with a poor echocardiographic window and in those
with diastolic dysfunction.401 In patients with LEAD, heart failure may be
associated with reduced patency after endovascular therapy.402 TTE
and natriuretic peptides can also be proposed in patients with claudica-
tion, even if no revascularization is planned.
12.2.3 Peripheral arterial diseases in patients with heart
failure
Observational studies and meta-analyses consistently show that the
presence of LEAD in heart failure patients is an independent predictor
of hospitalizations and mortality.376–379,403 In the Heart Failure: A
Controlled Trial Investigating Outcomes of Exercise Training (HF-
ACTION) study, LEAD was reported in 7% of patients with heart
failure and LV ejection fraction <35% and was associated with an
increased risk of all-cause hospitalization and mortality (HR 1.31, P =
0.011).376 Other studies reported an increased risk for progressive
heart failure (HR 1.35, P = 0.03), all-cause mortality (HR 1.36, P <
0.001)404 and CV mortality (HR 1.31, P = 0.02).405 Among hospitalized
patients with heart failure, the prevalence of subclinical (ABI <_0.90)
and symptomatic LEAD was 19% and 7%, respectively, and was associ-
ated with increased cardiac and all-cause mortality.378 Therefore, in
heart failure patients, screening for PADs may be considered.
Finally, flash pulmonary oedema may be due to severe RAS (see
section 9.2). Therefore, in patients with this condition, testing for
RAS may be considered.
12.3 Peripheral arterial diseases and
atrial fibrillation
12.3.1 General considerations
Ageing is a strong risk factor for AF406 and PADs, thus a frequent
coexistence of the two conditions is expected. In an analysis from the
Cardiovascular Health Study, LEAD was associated with a higher risk
of AF (HR 1.52, P < 0.01).407
Despite a considerable variability in BP due to the beat-to-beat
variability in stroke volume, ABI appears to be a reliable method to
detect unknown LEAD in patients with AF.408 In patients with AF
receiving anticoagulant treatment, abnormal ABI was an independent
predictor of all-cause death and major bleeding complications.409
Among 41 882 patients hospitalized for LEAD, the prevalence of
AF was 13%.406 Those with AF tend to be older, more often hyper-
tensive, female and with diabetes, CKD, CAD and/or heart failure
than patients in sinus rhythm. LEAD was overall more severe in
patients with AF as assessed by the Rutherford classification. In-
hospital complications, including renal failure, MI, stroke, infections
and death, occurred more frequently in the presence of AF. In other
studies, AF associated with LEAD was an independent predictor of
stroke, amputation and death.410,411 In the REACH registry, AF was
present in 10% of patients with LEAD.84 Compared with patients
without AF, the two-year CV and all-cause mortality was higher,
7.7% and 5.6% vs. 2.5% and 1.6%, respectively (P < 0.001 for both).
Those with AF also had higher incidences of heart failure, unstable
angina and severe bleeding.
12.3.2 Antithrombotic treatment in patients with atrial
fibrillation
Except for recent stenting, patients with PADs and AF should mostly
be on OACs alone. See section 5.3.
12.4 Peripheral arterial diseases and
valvular heart disease
PADs are common among patients with VHD, especially among
the elderly with symptomatic aortic stenosis. The presence of
LEAD is captured within the scores used to predict outcome after
cardiac surgery.412 Among patients with symptomatic aortic
stenosis not eligible for surgical aortic valve replacement, the
prevalence of LEAD is as high as 40%.413–415 It often coexists with
other manifestations of systemic atherosclerosis, including CAD
and cerebrovascular disease. This has an impact on patient care
with respect to the timing of coronary revascularization, if
needed,366 and the vascular access site for transcatheter aortic
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valve implantation (TAVI).416 Systematic CT scan imaging of the
aorta, including all major peripheral arteries, has become the
standard of care in patients eligible for TAVI.
12.5 Peripheral arterial diseases and
vascular access site for cardiac
interventions
Patient evaluation for the presence of LEAD and UEAD is pivotal for
access site choice in patients eligible for TAVI and their diagnosis has
a great impact on clinical outcome after TAVI because of the
increased rate of peri- and post-procedural complications.417,418 The
presence of LEAD or UEAD is an independent predictor of mortality
following TAVI with both percutaneous and surgical access, inde-
pendent of the occurrence of vascular complications.417,419 The use
of low-profile devices for TAVI and alternative access sites, such as
direct aortic, carotid or subclavian, may also reduce vascular
complications.
Acute limb ischaemia is a complication of intra-aortic balloon
pump insertion in the setting of cardiogenic shock or in the pro-
phylaxis of low output syndrome. LEAD is a major risk factor for
this complication and preliminary iliac artery stenting with the use
of an unsheathed device may avoid such complications.420 These
complications are also common in LV assist device recipients,
where sheaths are usually larger, resulting in higher 30-day mortal-
ity in patients with LEAD.421 The added risk of underlying LEAD is
not clearly established in that particular setting and deserves addi-
tional investigations. These patients often need lower limb revas-
cularization and surgical vascular closure when weaned off LV
assist devices.
Recommendations on the management of cardiac conditions associated with peripheral arterial diseases
Recommendations Classa Levelb
PADs and heart failure
Full vascular assessment is indicated in all patients considered for heart transplantation or cardiac assist device implantation. I C
In patients with symptomatic PADs, screening for heart failure with TTE and/or natriuretic peptides assessment should be
considered.
IIa C
Screening for LEAD may be considered in patients with heart failure. IIb C
Testing for renal artery disease may be considered in patients with flash pulmonary oedema. IIb C
PADs and atrial fibrillationc
In patients with LEAD and atrial fibrillation, oral anticoagulation:83
 is recommended with a CHA2DS2-VASc score >_2 I A
 should be considered in all other patients. IIa B
PADs and valvular heart disease
Screening for LEAD and UEAD is indicated in patients undergoing TAVI or other structural interventions requiring an
arterial approach. I C
CHA2DS2VASC = Congestive heart failure, Hypertension, Age >_75 (2 points), Diabetes mellitus, Stroke or TIA (2 points), Vascular disease, Age 65–74 years, Sex category;
LEAD = lower extremity artery disease; PADs = peripheral arterial diseases; TAVI = transcatheter aortic valve implantation; TTE = transthoracic echocardiography; UEAD =
upper extremity artery disease.
aClass of recommendation.
bLevel of evidence.
cFor more detail please refer to chapter 5.
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..13. Gaps in evidence
Rapid changes in therapeutic techniques create the situation in which
clinical practice tends to follow technical developments without evidence
from RCTs. In addition, RCTs often yield conflicting results because of
technical evolution. Moreover, PADs may involve multiple sites, creating
a large number of clinical scenarios to investigate. All these contribute to
the broad spectrum of gaps in evidence, of which the most relevant are
listed in Table 10. The current background information and detailed dis-
cussion of the data for the following section of these Guidelines can be
found in ESC CardioMed.
Table 10 Main gaps in evidence in the management of patients with peripheral arterial diseases
CAD = coronary artery disease; CAS = carotid artery stenting; CLTI = chronic limb-threatening ischaemia; DAPT= dual antiplatelet therapy; LEAD = lower extremity artery
disease; PADs = peripheral arterial diseases; RAS = renal artery stenosis; RCT = randomized clinical trial.
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14. To do and not to do messages from the Guidelines
Recommendations Classa Levelb
General recommendations on the management of patients with PADs
In healthcare centres, it is recommended to set up a multidisciplinary Vascular Team to make decisions for the management of
patients with PADs.
I C
It is recommended to implement and support initiatives to improve medical and public awareness of PADs, especially cerebro-
vascular and lower extremity artery diseases.
I C
Recommendations in patients with PADs: best medical therapy
Smoking cessation is recommended in all patients with PADs. I B
A healthy diet and physical activity are recommended for all patients with PADs. I C
Statins are recommended in all patients with PADs. I A
In patients with PADs, it is recommended to reduce LDL-C to < 1.8 mmol/L (70 mg/dL) or decrease it by >_ 50% if baseline val-
ues are 1.8–3.5 mmol/L (70–135 mg/dL).
I C
In diabetic patients with PADs, strict glycaemic control is recommended. I C
Antiplatelet therapy is recommended in patients with symptomatic PADs. I Cc
In patients with PADs and hypertension, it is recommended to control blood pressure at < 140/90 mmHg. I A
Recommendations on antithrombotic therapy in patients with PADs
In patients with symptomatic carotid stenosis, long-term SAPT is recommended. I A
Dual antiplatelet therapy with aspirin and clopidogrel is recommended for at least 1 month after CAS. I B
Long-term SAPT is recommended in symptomatic patients. I A
Long-term SAPT is recommended in all patients who have undergone revascularization. I C
SAPT is recommended after infra-inguinal bypass surgery. I A
Because of the lack of proven benefit, antiplatelet therapy is not routinely indicated in patients with isolatedd
asymptomatic LEAD.
III A
In patients with PADs and AF, OAC is recommended when the CHA2DS2-VASc score is >_ 2 I A
Recommendations for imaging of extracranial carotid arteries
DUS (as first-line), CTA and/or MRA are recommended for evaluating the extent and severity of extracranial carotid stenoses. I B
When CAS is being considered, it is recommended that any DUS study be followed either by MRA or CTA to evaluate the
aortic arch, as well as the extra- and intracranial circulation.
I B
When CEA is considered, it is recommended that the DUS stenosis estimation be corroborated either by MRA or CTA (or by
a repeat DUS study performed in an expert vascular laboratory).
I B
Recommendations on revascularization in patients with symptomatic carotid diseasee
CEA is recommended in symptomatic patients with 70–99% carotid stenoses, provided the documented procedural death/
stroke rate is < 6%.
I A
When decided, it is recommended to perform revascularization of symptomatic 50–99% carotid stenoses as soon as possible,
preferably within 14 days of symptom onset.
I A
Revascularization is not recommended in patients with a < 50% carotid stenosis. III A
Continued
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Recommendations for management of vertebral artery stenoses
Revascularization of asymptomatic vertebral artery stenosis is not indicated, irrespective of the degree of severity. III C
Recommendations on the management of acute mesenteric ischaemia
In patients with suspected acute mesenteric ischaemia, urgent CTA is recommended. I C
Recommendations for management of chronic mesenteric artery disease
In patients with suspected CMI, DUS is recommended as the first-line examination. I C
In patients with symptomatic multivessel CMI, revascularization is recommended. I C
In patients with symptomatic multivessel CMI, it is not recommended to delay revascularization in order to improve the nutri-
tional status.
III C
Recommendations for diagnostic strategies for RAD
DUS (as first-line), CTAf and MRAg are recommended imaging modalities to establish a diagnosis of RAD. I B
Renal scintigraphy, plasma renin measurements before and after ACEI provocation and vein renin measurements are not rec-
ommended for screening of atherosclerotic RAD.
III C
Recommendations for treatment strategies for RAD
ACEIs/ARBs are recommended for treatment of hypertension associated with unilateral renal artery stenosis. I B
Calcium channel blockers, beta-blockers and diuretics are recommended for treatment of hypertension associated with RAD. I C
Routine revascularization is not recommended in renal artery stenosis secondary to atherosclerosis. III A
Recommendations for ABI measurement
Measurement of the ABI is indicated as a first-line non-invasive test for screening and diagnosis of LEAD. I C
In the case of incompressible ankle arteries or ABI >1.40, alternative methods such as the toe-brachial index, Doppler wave-
form analysis or pulse volume recording are indicated.
I C
Recommendations on imaging in patients with LEAD
DUS is indicated as a first-line imaging method to confirm LEAD lesions. I C
DUS and/or CTA and/or MRA are indicated for anatomical characterization of LEAD lesions and guidance for optimal revascu-
larization strategy.
I C
The data from an anatomical imaging test should always be analysed in conjunction with symptoms and haemodynamic tests
prior to a treatment decision.
I C
Recommendations for the management of patients with intermittent claudication
On top of general prevention, statins are indicated to improve walking distance. I A
In patients with intermittent claudication, supervised exercise training is recommended. I A
In patients with intermittent claudication, non-supervised exercise training is recommended when supervised exercise training
is not feasible or available.
I C
Recommendations on revascularization of aorto-iliac occlusive lesionsh
An endovascular-first strategy is recommended for short (i.e. <5 cm) occlusive lesions. I C
Recommendations on revascularization of femoro-popliteal occlusive lesionsg
An endovascular-first strategy is recommended in short (i.e. <25 cm) lesions. I C
In patients who are not at high risk for surgery, bypass surgery is indicated for long (i.e. >_25 cm) superficial femoral artery
lesions when an autologous vein is available and life expectancy is > 2 years.
I B
The autologous saphenous vein is the conduit of choice for femoro-popliteal bypass. I A
Continued
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Recommendations on revascularization of infra-popliteal occlusive lesions
In the case of CLTI, infra-popliteal revascularization is indicated for limb salvage. I C
For revascularization of infra-popliteal arteries, bypass using the great saphenous vein is indicated. I A
Recommendations on the management of CLTI
Early recognition of tissue loss and/or infection and referral to the vascular team is mandatory to improve limb salvage. I C
In patients with CLTI, assessment of the risk of amputation is indicated. I C
In patients with CLTI and diabetes, optimal glycaemic control is recommended. I C
For limb salvage, revascularization is indicated whenever feasible. I B
In patients with CLTI, stem cell/gene therapy is not indicated. III B
Recommendations for the management of patients presenting with acute limb ischaemia
In the case of neurological deficit, urgent revascularization is indicated.i I C
In the absence of neurological deficit, revascularization is indicated within hours after initial imaging in a case-by-case decision. I C
Heparin and analgesics are indicated as soon as possible. I C
Recommendations on screening for carotid disease in patients undergoing CABG surgery
In patients undergoing CABG, DUS is recommended in patients with a recent (<6 months) history of TIA/stroke. I B
Screening for carotid stenosis is not indicated in patients requiring urgent CABG with no recent stroke/TIA. III C
Recommendations on the management of carotid stenosis in patients undergoing CABG surgery
It is recommended that the indication (and, if so, the method and timing) for carotid revascularization be individualized after dis-
cussion within a multidisciplinary team, including a neurologist.
I C
In patients scheduled for CABG, with a recent (<6 months) history of TIA/stroke, carotid revascularization is not recom-
mended in those with carotid stenosis <50%.
III C
In neurologically asymptomatic patients scheduled for CABG, routine prophylactic carotid revascularization in patients with a
70–99% carotid stenosis is not recommended.
III B
Recommendations for screening and management of concomitant LEAD and CAD
In patients with LEAD, radial artery access is recommended as the first option for coronary angiography/intervention. I C
Recommendations on the management of cardiac conditions associated with PADs
Full vascular assessment is indicated in all patients considered for heart transplantation or cardiac assist device implantation. I C
In patients with LEAD and atrial fibrillation, OAC is recommended with a CHA2DS2-VASc score >_2. I A
Screening for LEAD and UEAD is indicated in patients undergoing TAVI or other structural interventions requiring an arterial
approach. I C
ABI = ankle-brachial index; ACEI = angiotensin-converting enzyme inhibitor; AF = atrial fibrillation; ARB = angiotensin-receptor blocker; CABG = coronary artery bypass graft-
ing; CAS = carotid artery stenting; CEA = carotid endarterectomy; CLTI = chronic limb-threatening ischaemia; CMI = chronic mesenteric ischaemia; CTA = computed tomog-
raphy angiography; DUS = duplex ultrasound; eGFR = estimated glomerular filtration rate; LDL-C = low-density lipoprotein cholesterol; LEAD = lower extremity artery
disease; MRA = magnetic resonance angiography; OAC = oral anticoagulation; PADs = peripheral arterial diseases; RAD = renal artery disease; SAPT = single antiplatelet ther-
apy; TAVI = transcatheter aortic valve implantation; TIA = transient ischaemic attack; UEAD = upper extremity artery disease. CHA2DS2-VASc score is calculated as follows:
congestive heart failure history (1 point), hypertension (1 point), age >75 years (2 points), diabetes mellitus (1 point), stroke/TIA or arterial thromboembolic history (1 point),
vascular disease history (1 point), age 65–74 years (1 point), sex category (1 point if female).
aClass of recommendation.
bLevel of evidence.
cEvidence is not available for all sites. When evidence is available, recommendations specific for the vascular site are presented in corresponding sections.
dWithout any other clinical cardiovascular condition requiring antiplatelet therapy (e.g. coronary artery disease or other multisite artery diseases).
eStroke or TIA occurring within 6 months.
fWhen eGFR is >_ 60 mL/min.
gWhen eGFR is >_ 30 mL/min.
hThese recommendations apply for patients with intermittent claudication and severe chronic limb ischaemia.
iIn this case, imaging should not delay intervention.
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15. Web addenda and companion
document
All Web figures and Web tables are available at the European Heart
Journal online and also via the ESC Web site at: https://www.escar
dio.org/Guidelines/Clinical-Practice-Guidelines/Peripheral-Artery-
Diseases-Diagnosis-and-Treatment-of
The questions and answers companion document for these guide-
lines is available via this same link.
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